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ABSTRACT
Abstract
Human herpesvirus 6 (HHV-6) 
was identified from patients 
with HIV and lymphoprolifera-
tive diseases in 1986. It is a 
β-herpesvirus and is divided 
into two subgroups, variants A 
and B. HHV-6 variant B is the 
cause of exanthema subitum, 
while variant A has not yet 
definitely proven to cause any 
disease. HHV-6, especially 
variant A, is a highly neurotro-
pic virus and has been associ-
ated with many diseases of the 
central nervous system (CNS) 
such as encephalitis and mul-
tiple sclerosis (MS).
The present studies were 
aimed to elucidate the role of 
HHV-6 and its two variants in 
neurological infections. Special 
attention was given to study 
the possible role of HHV-6 in 
the pathogenesis of MS.
We studied the expression of 
HHV-6 antigens using immu-
nohistochemistry in brain au-
topsy samples from patients 
with MS and controls. HHV-6 
antigen was identified in 70% 
of MS specimens whereas 30% 
of control specimens expressed 
HHV-6 antigen. In addition, 
HHV-6 antigen was associated 
with elevated expression of tis-
sue plasminogen activator 
(tPA), an enzyme taking part 
in both neuronal development 
and degeneration.
In order to study the role of 
HHV-6 in MS further, serum 
and cerebrospinal fluid (CSF) 
samples were collected from 
patients with MS and patients 
with other neurological diseas-
es (OND) from patients visiting 
Helsinki University Central 
Hospital Neurological Outpa-
tient Clinic during the years 
2003 and 2004. A total of 27 
patients with clinically definite 
MS (CDMS) and 19 patients 
with clinically possible MS 
(CPMS) and age- and gender-
matched control patients with 
OND were included. In addi-
tion, we studied 53 children 
with suspected encephalitis. 
Samples were consecutively 
collected from the first and last 
quarter of the year 1995, from 
the sample series sent to the 
Department of Virology, Uni-
versity of Helsinki, for sus-
pected viral encephalitis.
We developed an immunofluo-
rescence IgG-avidity assay for 
the detection of primary HHV-
6A and HHV-6B infection. For 
HHV-6B antibodies, no differ-
ences were observed between 
patients with MS and OND. 
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For HHV-6A both seropreva-
lence and mean titers were 
significantly higher in MS com-
pared to OND. HHV-6A low-
avidity IgG antibodies, sugges-
tive of primary infection, were 
found in serum of two, three 
and one patient with CDMS, 
CPMS and OND, respectively. 
From pediatric patients with 
suspected encephalitis, six se-
rum samples (11.3%) con-
tained low-avidity antibodies, 
indicating a temporal associa-
tion between HHV-6A infection 
and onset of encephalitis. From 
these six samples one had 
HHV-6 DNA in serum and two 
in CSF.
Three out of 26 patients with 
CDMS and four out of 19 pa-
tients with CPMS had HHV-6 
antibodies in their CSF com-
pared to none of the patients 
with OND (p=0.06 and 
p=0.01, respectively). When 
HHV-6 antibodies were com-
pared to the total IgG in serum 
and CSF, two patients with 
CDMS and three patients with 
CPMS appeared to have specif-
ic intrathecal synthesis of 
HHV-6A antibodies. In addi-
tion, oligoclonal bands (OCB) 
were observed in the CSF of 
five out of nine MS patients 
tested, and in two the OCBs 
reacted specifically with HHV-6 
antigen, which is a novel find-
ing. These results indicate 
HHV-6 specific antibody pro-
duction in the CNS and sug-
gest that there is a subset of 
MS patients with an active or 
chronic HHV-6A infection in 
the CNS that might be involved 
in the pathogenesis of MS. 
Our studies suggest that HHV-6 
is an important causative or 
associated virus in some neu-
rological infections, such as 
encephalitis and it might con-
tribute to the development of 
MS, at least in some cases. In 
conclusion, HHV-6 is a neuro-
tropic virus that should be tak-
en into consideration when 
studying acute and chronic 
CNS diseases of unknown ori-
gin.
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Ihmisen herpesvirus 6 (HHV-6) 
eristettiin HIV-positiivisen lym-
foproliferatiivisista sairauksista 
kärsivien potilaiden verestä 
vuonna 1986. HHV-6 kuuluu 
β-herpesvirusten ryhmään ja 
esiintyy kahtena eri variantti-
na, A ja B. HHV-6 variantti B:n 
on todettu aiheuttavan vauva-
rokkoa. HHV-6 variantti A:n ei 
ole kiistatta todistettu aiheutta-
van mitään tautia, vaikkakin 
hyvin hermostohakuisena vi-
ruksena se on yhdistetty kes-
kushermoston sairauksiin ku-
ten aivotulehdukseen ja aivo-
jen pesäkekovettumatautiin 
(multippeli skleroosi, MS-tau-
ti). 
Väitöskirjatutkimuksen tarkoi-
tuksena oli tutkia HHV-6:n ja 
sen kahden eri variantin aihe-
uttamia keskushermostoinfek-
tioita. Väitöskirjan keskeisenä 
tavoitteena oli ennenkaikkea 
tutkia myös HHV-6:n osuutta 
MS-taudin synnyssä ja kehityk-
sessä. 
Tutkimme HHV-6-proteiinien 
ilmenemistä MS-tautia sairas-
taneiden potilaiden ruumiin-
avauksen yhteydessä saaduista 
aivokudosnäytteistä 
ja vertasimme tulok-
sia kontrollipotilai-
den aivokudoslöy-
döksiin. HHV-6 an-
tigeeniä todettiin 70 
%:lla MS-tautia sairastaneiden 
potilaiden aivokudoksessa, 
kun taas verrokeilla vastaava 
luku oli 30 %. Lisäksi havait-
simme, että HHV-6:n antigee-
nin ilmeneminen liittyi kohon-
neeseen kudostyypin plasmi-
nogeenin aktivaattorin (t-PA) 
tasoon.
Tutkiaksemme tarkemmin 
HHV-6:n osallisuutta MS-tau-
din synnyssä ja kehityksessä 
keräsimme seerumi- ja likvori-
näytteitä MS-tautia sairastavilta 
potilailta sekä verrokkipotilail-
ta. Näytteet kerättiin Helsingin 
yliopistollisen keskussairaalan 
neurologian poliklinikalla vuo-
sina 2003–2004. Tutkimusai-
neistossa 27 potilaalla todettiin 
varma ja 19 mahdollinen MS-
diagnoosi. Potilaille valittiin 
ikään ja sukupuoleen perustu-
en vastaavat verrokit potilaista, 
jotka sairastivat jotain muuta 
hermoston sairautta. Sisälly-
timme aineistoon myös 53 ai-
votulehdusepäilyn takia tutki-
muksiin lähetetyn lapsipotilaan 
näytteet. Seerumit kerättiin ar-
kistomateriaalista, jotka oli lä-
hetetty Helsingin yliopiston vi-
rologian osastolle Haartman-
Tiivistelmä 
 (Summary in Finnish)
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instituuttiin, vuoden 1995 en-
simmäisellä ja viimeisellä nel-
jänneksellä.
Kehitimme immunofluoresens-
siin perustuvan IgG-aviditeetti-
testin HHV-6 variantti A:n ja 
variantti B:n primaari-infekti-
oiden toteamiseksi seerumista. 
HHV-6B tyypin vasta-aineissa 
ei todettu mitään eroa eri ryh-
mien välillä, mutta HHV-6A 
tyypin vasta-aineita löytyi use-
ammin ja suurempina pitoi-
suuksina MS-tautia sairastavi-
en potilaiden seerumissa ver-
rattuna kontrollipotilaisiin. Pri-
maari-infektioon viittaavia ma-
tala-avidisia vasta-aineita löy-
dettiin kahdelta varmalta ja 
kolmelta mahdolliselta MS-po-
tilaalta ja yhdeltä muuta her-
moston sairautta sairastavalta 
potilaalta. Kuudella 53 aivotu-
lehdusepäilylapsesta (11.3 %) 
havaittiin matala-avidisia vas-
ta-aineita viitaten primaari-in-
fektioon. Yhdellä oli HHV-6 
DNA:ta seerumissa ja kahdella 
likvorissa. 
Likvorista löytyi HHV-6 vasta-
aineita kolmelta kliinisesti var-
malta MS-potilaalta ja neljältä 
mahdolliselta, kun taas kont-
rolliryhmässä ei kenelläkään 
ollut likvorissa HHV-6 vasta-
aineita (p=0.06 ja p=0.01). 
Kahdella kolmesta varmasta ja 
kolmella neljästä mahdollisesta 
MS-potilaasta vasta-aineiden 
tuotto näytti olevan aivoperäis-
tä, intratekaalista, kun verrat-
tiin HHV-6 spesifin vasta-ai-
neen tasoa seerumin ja likvorin 
IgG:n kokonaismäärään. Tä-
män lisäksi viidellä yhdeksästä 
tutkitusta MS-potilaasta todet-
tiin likvorissa oligoklonaalisia 
vyöhykkeitä ja kahdella poti-
laalla nämä vyöhykkeet reagoi-
vat spesifisesti HHV-6 antigee-
nin kanssa. Tällaista reaktiota 
ei MS-potilailla ole aikaisem-
min osoitettu. Tulokset viittaa-
vat, että osalla MS-potilaista 
saattaa olla aktiivinen tai kroo-
ninen HHV-6 infektio vaikutta-
en MS-taudin syntyyn ja kehi-
tykseen.
Väitöskirjan tutkimustulokset 
viittaavat siihen, että HHV-6 
on etiologinen tai myötävaikut-
taja tekijä joissakin keskusher-
moston infektioissa ja erityi-
sesti se  näyttäisi liittyvän MS-
tautiin, vaikkakin sen rooli 
taudin synnyssä ja kehitykses-
sä vaatii lisäselvittelyä. HHV-6 
on syytä ottaa huomioon tut-
kittaessa etiologialtaan tunte-
mattomia keskushermoston 
sairauksia.
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Herpesviridae
Herpesviridae is a large family 
of double-stranded DNA virus-
es containing more than one 
hundred recognized species, 
although it is likely that the 
identified herpesviruses thus 
far represents only a small 
fraction of their true number. 
Herpesviruses infecting a wide 
range of vertebrates and at 
least one herpesvirus infecting 
an invertebrate have been 
identified (Davison, 2002). 
Herpesviruses have a strict 
host specificity suggesting long 
co-evolution with their hosts. 
The name of the family is de-
rived from the Greek word her-
pein (= to creep) and refers to 
the latency and reoccurrence 
of the infections caused typi-
cally by herpesviruses. The 
Herpesviridae family is divided 
into three subfamilies: alpha-
herpesvirinae, betaherpesviri-
nae and gammaherpesvirinae. 
Human herpesviruses
Eight different herpesviruses 
infecting humans, abbreviated 
as HHV-1 to HHV-8, have been 
identified to date. It has been 
suggested, but not 
formally accepted, 
that HHV-6 vari-
ants A and B could 
be considered two 
separate viruses 
(Komaroff et al., 2006), in-
creasing the number of the 
members to nine. The first five 
and the last member of human 
herpesviruses are commonly 
known by their alternative 
names, while sixth and sev-
enth members are known as 
human herpesvirus 6 and 7, 
respectively (Table 1). The 
members of alphaherpesvirinae 
causes typically skin blisters. 
The members of gammaher-
pesvirinae have the potential 
to malignant transformation of 
the cell and typically cause 
lymphomas and Kaposi’s sar-
coma. Cytomegalovirus (CMV) 
and HHV-6 variant B, members 
of the betaherpesvirinae, cause 
mononucleosis and exanthema 
subitum (ES), respectively. The 
diseases caused by other two 
members of betaherpesvirinae, 
HHV-6 variant A and HHV-7, 
are not known, but some cases 
of ES might be caused by 
HHV-7 (Bruns et al., 2000), 
and HHV-6A has been associ-
ated with neurological infec-
tions (Boutolleau et al., 2006).
Review of the 
 literature
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Human herpesvirus 6
HHV-6, a member of the Rose-
olovirus genus within the Beta-
herpesvirinae subfamily, and 
its two variants A and B are 
further discussed in the follow-
ing sections.
History
Human herpes virus 6 (HHV-6) 
was for the first time isolated 
from patients with HIV and 
lymphoproliferative diseases in 
1986 (Salahuddin et al., 1986). 
Initially, the virus was named 
human B-lymphotropic virus 
(HBLV), due to its apparent 
tropism for B-lymphocytes. 
Soon it became evident that 
the virus had a much wider 
tropism and it actually prefer-
entially infected T-lymphocytes 
rather than B-lymphocytes, 
and was consequentially re-
named human herpesvirus 6. 
The second major break-
through in the natural history 
of the HHV-6 occurred in 1988, 
when a Japanese group 
showed by virus isolation and 
seroconversion that HHV-6 is 
the cause of exanthema subi-
tum (roseola infantum, sixth 
disease, ES) (Yamanishi et al., 
1988). In the late 1980s and 
Table 1. Human herpesviruses.
disease/symptoms subfamily/genus
HHV-1 Herpes simplex virus 1 (HSV-1)
oral/genital herpes 
(predominantly orofacial)
Alphaherpesvirinae/
Simplexvirus
HHV-2 Herpes simplex virus 2 (HSV-2)
oral/genital herpes 
(predominantly genital)
Alphaherpesvirinae/
Simplexvirus
HHV-3 Varicella-zoster virus (VZV) chickenpox, shingles
Alphaherpesvirinae/
Varicellovirus
HHV-4 Epstein-Barr virus (EBV) mononucleosis, lymphomas
Gammaherpesvirinae/
Lymphocryptovirus
HHV-5 Cytomegalovirus (CMV) mononucleosis, retinitis
Betaherpesvirinae/
Cytomegalovirus
HHV-6A Human herpesvirus 6 variant A
No clear disease associations, 
CNS symptoms?, multiple 
sclerosis?
Betaherpesvirinae/
Roseolovirus
HHV-6B Human herpesvirus 6 variant B
exanthema subitum, CNS 
symptoms?, epilepsy?
Betaherpesvirinae/
Roseolovirus
HHV-7 Human herpesvirus 7
roughly similar symptoms as 
HHV-6B
Betaherpesvirinae/
Roseolovirus
HHV-8
Kaposi’s sarcoma 
associated herpesvirus 
(KSHV)
Kaposi’s sarcoma, lymphomas Gammaherpesvirinae/Rhadinovirus
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early 1990s, a number of new 
virus strains were isolated and 
they seemed to fall into two 
classes (Schirmer et al., 1991), 
and variants A and B (HHV-6A 
and HHV-6B) were established. 
They differed in their genome 
and in their growth properties 
and cell tropism as well as in 
immunology (Ablashi et al., 
1991). The initial isolate ap-
peared to be variant A, while 
the variant behind ES was 
HHV-6B (Schirmer et al., 
1991). The primary infection 
was shown to be caused by 
variant B in the majority of the 
population in the U.S. (Dew-
hurst et al., 1993a). 
Since the early stages of HHV-6 
research, based on the patients 
from which HHV-6 (strain GS, 
variant A) was isolated, it was 
obvious to look for associa-
tions between HHV-6 and HIV 
and acquired immunodeficien-
cy syndrome (AIDS). Several 
articles described high levels 
of antibodies to HHV-6 in pa-
tients with HIV infection 
(Brown et al., 1988; Fox et al., 
1988; Krueger et al., 1988) and 
it was shown that HHV-6 can 
double-infect cells after prior 
HIV infection (Agut et al., 
1988; Agut et al., 1989; Lusso 
et al., 1989) and two pioneers, 
co-discoverer of HIV Dr. Robert 
Gallo, and Dr. Paulo Lusso 
suggested an association be-
tween HHV-6 with AIDS (Lusso 
and Gallo, 1994; Lusso and 
Gallo, 1995).
Already at the beginning it was 
shown that HHV-6 is a neuro-
tropic virus and can cause se-
vere CNS disease (Wakefield et 
al., 1988; Ishiguro et al., 1990; 
Asano et al., 1992; Merelli et 
al., 1992). The first publication 
reporting HHV-6 antibodies 
and DNA in multiple sclerosis 
was published soon after (Sola 
et al., 1993) and an association 
was suggested two years later 
(Challoner et al., 1995). Active 
HHV-6 infection was also asso-
ciated with chronic fatigue 
syndrome (CFS) (Buchwald et 
al., 1990; Josephs et al., 1991; 
Buchwald et al., 1992).
The problem in unraveling the 
viral pathogenesis of HHV-6 is 
the commensalism and the 
ubiquitous nature of the virus. 
The latency complicates the de-
tection of the active infection, 
not mention the recent discov-
ery that HHV-6 can integrate 
into the host chromosome thus 
interfering molecular diagnosis. 
Although much improvement 
has been made during the lat-
est years with respect to the 
molecular and cellular biology 
of the HHV-6 infection, much 
further investigation is needed.
Figure 1. Schematic presentation of typical herpesvirus structure. 
Double stranded DNA genome is packed inside the protein coat called 
nucleocapsid. The tegument layer covers the nucleocapsid. The outer 
layer, envelope, consists of lipids and glycoproteins.
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Structure and genome
HHV-6 shares a common struc-
ture with other herpesviruses. 
It is composed of three main 
structural elements; nucleo-
capsid, tegument and enve-
lope. The nucleocapsid con-
taining the viral genome has 
an icosahedral symmetry made 
up of 162 capsomers (Biberfeld 
et al., 1987). The tegument 
layer covers the nucleocapsid 
and is composed of a protein 
mixture. Finally the viral parti-
cle is covered by an envelope, 
in which the viral glycopro-
teins are embedded (Figure 1). 
The genome of HHV-6 is linear 
double-stranded DNA mole-
cule. The size of the DNA mol-
ecule is 160 to 162 kb depend-
ing on the variant and isolate. 
The genome consists of unique 
(U) region, which is 143 to 145 
kb in size and is flanked by 
terminal direct repeats (DR). 
DR regions are approximately 
8 to 9 kb. Three additional re-
peat regions, R1, R2 and R3 
truncate the U region in the 
immediate early A (IE-A) re-
gion (Figure 2). Each end of 
the DRs is composed of telo-
meric repeats (GGGTTA)n 
(Thomson et al., 1994). Telo-
meric repeats have been postu-
lated to have a role in DNA 
replication and maintenance of 
the viral genome in latently 
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infected cells (Gompels and 
Macaulay, 1995; Gompels et 
al., 1995). The genes within 
the DRs are designated DR1 to 
DR8 and genes within the U 
region are called U1 to U100 
(Figure 2).
The similarity between vari-
ants A and B at the nucleotide 
level is 90% (Gompels and 
Macaulay, 1995; Dominguez et 
al., 1999). The similarity is 
highest in the central part of 
the genome and decreases 
when approaching genomic 
ends, being lowest at the IE re-
gion (Dominguez et al., 1999; 
Isegawa et al., 1999). Although 
high variation between vari-
ants exists, IE region is highly 
conserved among HHV-6B iso-
lates (Stanton et al., 2003). 
Nine open reading frames 
(ORFs) found in the HHV-6B 
genome are absent in HHV-6A 
(Dominguez et al., 1999) and, 
on the other hand, nine ORFs 
present in the HHV-6A genome 
cannot be found in HHV-6B 
(Gompels et al., 1995).
HHV-6 variants A and B
Although HHV-6B is the cause 
of ES (Yamanishi et al., 1988), 
HHV-6A has not been unequiv-
ocally shown to cause any dis-
ease. These two variants differ 
in epidemiology, in vitro 
growth properties, reactivity 
with monoclonal antibodies, 
restriction endonuclease map-
ping and nucleotide and amino 
acid sequences (Wyatt et al., 
1990; Ablashi et al., 1991; Au-
bin et al., 1991; Schirmer et 
al., 1991; Chandran et al., 
1992; Gompels et al., 1993; Ya-
mamoto et al., 1994; Isegawa 
et al., 1999). The differences 
are discussed in detail in the 
appropriate paragraphs. Some 
researchers have suggested 
that these two variants could 
actually be considered two 
separate β-herpesviruses (Ko-
maroff et al., 2006). Neverthe-
less, the International Commit-
tee on Taxonomy of Viruses 
regards HHV-6A and HHV-6B 
as strains or different isolates, 
not separate viruses (Büchen-
Osmond, 2008).
Cell tropism
Although initially named hu-
man B-lymphotropic virus, 
HHV-6 is predominantly re-
garded as T-cell tropic. In reali-
ty, HHV-6 infects a wide variety 
of cell types (Ablashi et al., 
1987; Ablashi et al., 1989). All 
isolates including both variants 
A and B grow in activated pe-
ripheral blood mononuclear 
cells; however, the variants can 
be distinguished by culture in 
continuous T-cell lines. HHV-6A 
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infects efficiently HSB-2 cell 
line, but not MOLT-3 cells. 
HHV-6B infects MOLT-3 cells, 
but not HSB-2 cells (Ablashi et 
al., 1991). However, intervari-
ant variation between different 
isolates might also exist.
HHV-6 is a neurotropic virus 
and has been shown to infect 
primary human fetal astrocytes 
(He et al., 1996), glioblastoma 
cells (Ablashi et al., 1989), 
neuroblastoma cells (Levy et 
al., 1990) and embryonic glia 
(Tedder et al., 1987). HHV-6A 
seems to be more neurotropic 
than HHV-6B is (Hall et al., 
1998; Ahlqvist et al., 2005; De 
Bolle et al., 2005b). Differential 
tropism has been observed in 
astrocytes (Donati et al., 2005; 
Ahlqvist et al., 2006) and in 
oligodendrocytes. In astrocytes 
only HHV-6A is able to com-
plete a full replication cycle 
(Ahlqvist et al., 2006). HHV-
6A is able to form an active 
infection and latent infection 
after active phase while HHV-
6B forms an abortive infection 
in the oligodendrocytic cell 
line MO3.13 (Ahlqvist et al., 
2005).
Replication cycle
CD46, or membrane cofactor 
protein (MCP), is the cellular 
receptor for HHV-6 (Santoro et 
al., 1999) (Figure 3). CD46 is 
present in all nucleated cells 
(Liszewski et al., 1991) and 
might partially explain why 
HHV-6 can infect such a wide 
variety of human cells and the 
restriction of permissive spe-
cies. HHV-6 glycoproteins H, L 
and Q (gH, gL and gQ) form a 
complex that associates with 
CD46 (Mori et al., 2003). gH is 
the glycoprotein that directly 
binds to the short consensus 
repeat domains SCR2 and 
SCR3 of CD46 (Santoro et al., 
2003). Glycoprotein B (gB) is 
not directly involved in virus-
CD46 interaction, but it has 
been shown to have a role in 
the fusion event as well (Take-
da et al., 1996). gB contains 
variant-specific epitopes and is 
a target for neutralizing anti-
bodies (Campadelli-Fiume et 
al., 1993; Takeda et al., 1996), 
which might contribute to the 
different cell tropisms of HHV-6 
variants. 
After attachment to the cell 
membrane by glycoprotein-
CD46 interaction, the viral en-
velope fuses with the cell 
membrane and nucleocapsid 
enters the cytoplasm. In the 
fusion both viral cholesterol 
within viral membrane (Huang 
et al., 2006) and cellular cho-
lesterol within plasma mem-
brane (Tang et al., 2008) are 
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required for successful entry 
into the cell. The transporta-
tion mechanisms are not well 
understood, but it is hypothe-
sized that nucleocapsid is 
transported in a similar way as 
HSV-1 (Lycke et al., 1988) and 
CMV (Ogawa-Goto et al., 
2003), i.e. by association with 
the microtubule network. After 
reaching the nuclear pore com-
plex the viral DNA is released 
inside the nucleus, where the 
virus uses the cellular tran-
scription and translation ma-
chinery to produce viral pro-
teins. Immediate early (IE) or 
α proteins are produced within 
few hours after the viral enter 
to the cell, and these proteins 
regulate the transcription of 
the other genes. Subsequently, 
IE proteins initiate the tran-
scription of early (E) or β 
genes. E gene products are 
mainly involved in DNA me-
tabolism and replication. Late 
(L) or γ genes, which are ei-
ther partially or fully depen-
dent on viral DNA replication, 
are transcribed last. Products 
of L genes are structural pro-
teins and other proteins that 
are involved in virion assem-
bly. Interestingly, Øster and 
Höllsberg (2002) have shown 
that many of the genes that are 
E or even L are actually de-
tected as early as one hour af-
ter infection. This observation 
might suggest that HHV-6 
genes are leaky or might be 
controlled by a more complex 
mechanism. Indeed, in the 
case of HCMV and HSV the 
temporal gene expression pat-
tern follows five kinetic classes 
rather than three. Genes are 
subdivided into α (immediate 
early), β1 (early), β2 (early 
late), γ1 (leaky late) and γ2 
(true late) genes (Roizman et 
al., 2007; Mocarski et al., 
2007). In Øster and Höllsberg 
studies (2002) the HHV-6B 
genes seemed to fall in six dif-
ferent classes. 
DNA replication of the HHV-6 
needs seven virally encoded 
proteins. Replication is initiat-
ed by the binding of the origin 
binding protein (encoded by 
U73 gene) to the origin of lytic 
replication (ori-lyt) evoking 
denaturation of a portion of 
the circular genome (Dewhurst 
et al., 1993b; Inoue et al., 
1994; Inoue and Pellett, 1995). 
Three viral proteins, encoded 
by U43, U74 and U77, form a 
heterotrimeric helicase/pri-
mase complex, which main-
tains the DNA helix unfolded 
and provides RNA primers to 
the lagging-strand synthesis 
(Nicholas, 1994). Major DNA-
binding protein encoded by 
U41 stabilizes the single-
stranded DNA until the second 
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strand is produced by DNA 
polymerase encoded by U38 
gene (Teo et al., 1991). U27 
encodes a protein that binds 
specifically to DNA polymerase 
acting as a processivity factor 
(Zhou et al., 1994; Lin and 
Ricciardi, 1998). Besides these 
seven proteins, four additional 
proteins encoded by U79-80 
genes, and alternatively spliced 
after translation, have been 
suggested to have a role in vi-
ral DNA replication (Taniguchi 
et al., 2000).
The replication proceeds by 
rolling-circle replication and 
concatameric progeny DNA 
strands are encapsidated by 
the interaction of the cleavage 
and packaging proteins with 
the specific packaging signals 
pac1 and pac2 at the both ends 
of the DNA molecule (Thom-
son et al., 1994; Deng and De-
whurst, 1998).
Capsids bud out from the nu-
cleus. From the membrane of 
the nucleus the capsid acquires 
Figure 3. HHV-6 replication cycle. HHV-6 enters the cell using CD46 as 
a cellular receptor. The genes are transcribed and translated in three 
kinetic classes, immediate early (IE), early (E) and late (L) genes. HHV-6 
egress the cell by endocytosis. The replication cycle events; entry, repli-
cation, maturation and egress, are described in the text. Modified from 
De Bolle et al. (2005a).
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a temporal membrane that 
does not include glycoproteins. 
In contrast to other herpesvi-
ruses HHV-6 glycoproteins are 
not present on the plasma 
membrane of an infected cell 
(Cirone et al., 1994; Torrisi et 
al., 1999). HHV-6 glycoproteins 
accumulate either to the Golgi 
complex (where they are gly-
cosylated) or to anullate lamel-
lae (stack of narrow mem-
branes present in the cytoplasm 
near the rough endoplasmic 
reticulum). Capsids acquire 
their envelope that contains 
glycoproteins from the Golgi 
complex or anullate lamellae 
(Cardinali et al., 1998) and 
mature virus particles are re-
leased from the cell by exocy-
tosis. Recently, it has been 
suggested that mature viral 
particles are transferred to the 
plasma membrane within mul-
tivesicular body-like compart-
ments that include small vesi-
cles. Mature virions together 
with small vesicles are released 
to the extracellular space by an 
exosomal pathway (Mori et al., 
2008).
Epidemiology
The primary infection by either 
or both variants occurs during 
the first three years of life in 
up to 90% children throughout 
the world. An initial report on 
seroprevalence showed a really 
low (2%) seroprevalence 
among healthy blood donors 
and AIDS patients without 
lymphoma (0%) in U.S. (Sala-
huddin et al., 1986). Krueger 
et al. (1988) and Ablashi et al. 
(1988) then showed that the 
seroprevalence was approxi-
mately one fourth in the gen-
eral population when very 
strict diagnostic criteria was 
used, but the seroprevalence 
increased to 63%, if lower and 
borderline antibody titers were 
included. Therefore, it is likely 
that these early conflicting re-
sults were due to the subjectiv-
ity, sensitivity and interpreta-
tion of fluorescence assays, or 
the virus strain used as the 
source of the antigen, not to 
mention geographic variation. 
Over 90% newborns have ma-
ternal antibodies; these mater-
nal antibodies however, disap-
pear between birth and six 
months of age (Enders et al., 
1990). In some cases maternal 
antibodies can persist beyond 
one year thus overestimating 
the HHV-6 infection rates in 
young children in seropreva-
lence studies (Chokephaibulkit 
et al., 1997). The peak of 
HHV-6 infection occurs at the 
age of six to 15 months (Oku-
no et al., 1989; Enders et al., 
1990). A slight increase in the 
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seropositivity occurs during 
the first decade of life, but 
HHV-6 antibody titers show a 
decline with advancing age 
(Saxinger et al., 1988; Enders 
et al., 1990; Cermelli et al., 
1992; Parker and Weber, 1993; 
Baillargeon et al., 2000; Ihira 
et al., 2002). Overall, HHV-6 is 
a widespread virus with preva-
lences ranging from 60-100% 
in different geographical re-
gions (Linhares et al., 1991; 
Chua et al., 1996; Nielsen and 
Vestergaard, 1996; Tolfvenstam 
et al., 2000; Bhattarakosol et 
al., 2001). In Africa, HHV-6A 
infection seems to be more 
prevalent than HHV-6B infec-
tion in infants (M. Bates, Uni-
versity of London, personal 
communication).
HHV-6 diagnostics
The diagnostics of HHV-6 is a 
complicated issue. Many fea-
tures of HHV-6 make the diag-
nosis laborious and difficult to 
interpret; including two vari-
ants with different pathological 
properties, latency, integration 
into the genome and high 
prevalence among the popula-
tion (Koch, 2001; Dockrell, 
2003; Ward, 2005). Each of the 
above features should be taken 
into consideration when as-
sessing diagnostic approaches 
along with careful evaluation 
Figure 4. Virological features of primary HHV-6 infection (Ward, 2005).
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of the clinical picture. The 
most common problem in 
HHV-6 diagnosis is either lack 
of variant distinction or lack of 
distinction between primary 
infection, chronic infection or 
reactivation. Although reacti-
vation might happen in immu-
nocompromised patients, the 
clinical significance of the re-
activation is not clear (Clark 
and Griffiths, 2003). Primary 
infection can be diagnosed ei-
ther by the presence of DNA in 
serum during viremia at the 
acute phase in the absence of 
IgG antibodies or as the pres-
ence of low-avidity IgG anti-
bodies in serum at the late 
acute or convalescent phase 
(Figure 4). In the former case, 
HHV-6 DNA integration into 
the genome might lead to mis-
diagnosis (Tanaka-Taya et al., 
2004; Clark et al., 2006; Ward 
et al., 2006). The gold standard 
to diagnose primary infection 
is to detect IgG seroconversion 
between two serum samples. 
PCR and molecular diagnostics
Nucleic acid amplification 
methods, mainly PCR, have 
been used for detection of 
HHV-6 DNA in many body flu-
ids as well as in tissues. The 
clinical significance of a posi-
tive viral DNA finding in dif-
ferent body fluids is somewhat 
controversial. The most com-
mon problem in DNA amplifi-
cation is that one cannot dif-
ferentiate latent infection from 
active infection. In the general 
population there is a low copy 
number of viral DNA present 
in blood lymphocytes repre-
senting latent infection. Serum 
and plasma usually do not 
contain free viral DNA. In the 
absence of IgG, a high copy 
number in whole blood or the 
presence of any viral DNA in 
serum or plasma have been 
shown to occur during tran-
sient viremia during the acute 
phase (Figure 4) indicating pri-
mary infection (Asano et al., 
1989). This was shown by 
Chiu et al. (1998) to be the 
most reliable method after se-
roconversion to detect HHV-6 
primary infections, although 
occasionally viral DNA in 
plasma or a high copy number 
in whole blood was associated 
with other infections possibly 
representing HHV-6 reactiva-
tion. The major advantage of 
PCR is the possibility to distin-
guish the two variants from 
each other. Indeed, many vari-
ant-specific PCR methods have 
been developed.
Variant distinction can be 
made by using either variant-
specific primers that selectively 
amplify only one of the vari-
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ants or primers that amplify a 
fraction from both variants, 
which are further identified 
e.g. by the use of variant-spe-
cific probes in hybridization 
(Drobyski et al., 1993; Aubin 
et al., 1994). Real-time PCR 
methods have been developed 
for the quantification of the 
amount of genomes present in 
the samples (Safronetz et al., 
2003; Boutolleau et al., 2006). 
In many cases detection of 
DNA cannot reveal whether 
the infection is active or latent, 
although quantification may 
give indication. The expression 
of HHV-6 RNA on the other 
hand is a real marker of active 
infection and can be detected 
by the means of reverse tran-
scription PCR (Norton et al., 
1999; Yoshikawa et al., 2003; 
Alvarez-Lafuente et al., 2004; 
Pradeau et al., 2006). A nested 
step can be used in PCR to im-
prove sensitivity, but it might 
produce false-positive results 
and thus all of the amplified 
fragments are recommended to 
be sequenced and therefore 
the method is too laborious for 
the routine diagnostics.
Dr. Flamand and collaborators 
(Flamand et al., 2008) initiated 
a multicenter study, to evalu-
ate the differences and reliabil-
ity in different PCR methods 
used currently. The lack of 
standardized PCR assay might 
have led to discordant results 
in disease associations. The 
authors conclude that from six 
different real-time PCRs, three 
seemed to be most reliable and 
research and diagnostic labora-
tories should use similar or 
identical to those as reference 
in setting up their own HHV-6 
assay.
Multiplex-PCR assays have 
been developed to detect a va-
riety of human herpesviruses 
(Read and Kurtz, 1999; Mark-
oulatos et al., 2001) e.g. for 
screening purposes in CNS in-
fections. Microarray-based 
technology following multi-
plex-PCR has been developed 
to identify different herpesvi-
ruses (Jääskeläinen et al., 
2006; Jääskeläinen et al., 
2008).
Serological diagnostics
Maternal antibodies are pres-
ent in sera of infants under the 
age of approximately six 
months (Enders et al., 1990) 
and make the use of serology 
difficult in early childhood. Af-
ter the disappearance of the 
maternal antibodies, primary 
infection in children can be 
detected reliably by detection 
of seroconversion. The first se-
rum sample is taken immedi-
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ately after the symptoms and 
is usually negative for IgG. A 
follow-up sample is taken dur-
ing the convalescent phase one 
to two weeks after onset of 
symptoms and if positive, se-
roconversion is detected. IgM 
serology is not a reliable mark-
er of primary infection since it 
might be positive in reactiva-
tions and reinfections and fur-
thermore, it is not always posi-
tive in primary infections (Fox 
et al., 1988; Suga et al., 1992; 
Salonen et al., 2008).
IgG avidity can be used for the 
detection of primary infection 
in IgG-positive samples at the 
convalescent phase (Hedman 
et al., 1993). Initially after the 
primary infection B-cells pro-
duce antibodies that have a 
weak overall binding strength 
(low avidity) to the antigen. 
After B-cell maturation the an-
tibodies produced have higher 
overall binding strength (high 
avidity). The maturation of B-
cells in the case of HHV-6 in-
fection usually takes approxi-
mately four to six weeks and 
thus the diagnostic window for 
the detection of primary infec-
tion from the convalescent se-
rum is wide. The IgG-avidity 
methodology for the detection 
of primary HHV-6 infection 
was introduced in 1993 (Ward 
et al., 1993b) and shown to be 
specific for HHV-6 and not to 
cross-react with other herpes-
viruses (Ward et al., 1993a). 
Although it is generally 
claimed that HHV-6 variants A 
and B cross-react serologically 
with each other, some studies 
have reported different titers 
and prevalences for these two 
(Ongradi et al., 1999; Portolani 
et al., 2006). Portolani et al. 
(2006) were able two show a 
primary HHV-6A infection in 
an adult patient with encepha-
lomyelitis using HHV-6A and 
HHV-6B infected cells, and it 
was confirmed by variant-spe-
cific PCR. 
Clinical presentations and 
associations of HHV-6
Only one disease, ES, has been 
etiologically proven to be 
caused by HHV-6. However, 
many diseases have been as-
sociated with the virus and are 
discussed in the following sec-
tions.
HHV-6 primary 
infection in children
The primary infection of HHV-
6B occurs in developed coun-
tries before three years in over 
90% of the population (De 
Bolle et al., 2005a). Only a mi-
nority of the infants has typical 
ES symptoms. ES symptoms in-
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clude a high fever for approxi-
mately three days and a typical 
maculopapular rash that fol-
lows fever and resolves within 
three days. ES is often misdiag-
nosed as measles or rubella in 
countries where measles and 
rubella exist (Black et al., 1996; 
Tait et al., 1996; Oliveira et al., 
2003). In Finland, after the start 
of nationwide measles, mumps 
and rubella (MMR) vaccination 
program in 1982, pediatric en-
cephalitides associated with 
these viruses had vanished by 
1989 (Koskiniemi and Vaheri, 
1989) and measles and rubella 
were eliminated in 1996 (Pelto-
la et al., 1994; Peltola et al., 
2000). Anyhow, most HHV-6B 
primary infections are asymp-
tomatic. In some cases HHV-6B 
primary infection is associated 
with CNS symptoms, such as 
febrile seizures and convulsions 
(Caserta et al., 1994; Hall et al., 
1994; Ward et al., 2005), and 
even encephalopathy (Asano et 
al., 1992; Ward et al., 2005) or 
meningoencephalitis (Ishiguro 
et al., 1990; Yoshikawa et al., 
1992; Yanagihara et al., 1995). 
HHV-6B remains latent in blood 
cells and in salivary glands 
(Sada et al., 1996; Pereira et al., 
2004; Chen and Hudnall, 2006). 
It is not known at what age the 
variant A is acquired. 
HHV-6 primary infection 
in adults and reactivation/
reinfection
Primary infection, at least in 
the case of HHV-6B, in older 
children and adults is rare. Pri-
mary infection at later ages, in 
the light of other herpesvirus-
es, might be expected to cause 
a more severe disease (Ward, 
2005). Mononucleosis-like syn-
drome in patients negative for 
EBV and CMV has been sug-
gested to be caused by HHV-6 
(Steeper et al., 1990; Akashi et 
al., 1993; Goedhard et al., 
1995), although it is arguable 
whether these infections were 
primary infections or reactiva-
tions (Morris, 1993). Prolonged 
lymphadenopathy (Niederman 
et al., 1988; Irving and Cun-
ningham, 1990), fulminant 
hepatitis (Irving and Cunning-
ham, 1990; Sobue et al., 1991) 
and encephalomyelitis (Porto-
lani et al., 2006) have also 
been associated with primary 
HHV-6 infection in adults. 
HHV-6 DNA has been found in 
patients with sinus histiocyto-
sis with massive lymphade-
nopathy (Rosai-Dorfman dis-
ease) (Levine et al., 1992) and 
histiocytic necrotizing lymph-
adenitis (Kikuchi’s disease) 
(Sumiyoshi et al., 1993). 
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HHV-6 and central 
nervous system disease
Although usually benign, 
HHV-6 primary infection can 
invade the CNS and cause 
brain and spinal cord diseases 
(Kondo et al., 1993; Caserta et 
al., 1994; Lyall, 1996; Yoshika-
wa and Asano, 2000; Mannon-
en et al., 2007). Furthermore 
HHV-6 reactivations and pri-
mary infections in immuno-
competent elderly subjects can 
cause, albeit rarely, severe CNS 
complications such as enceph-
alitis and myelitis (Novoa et 
al., 1997; Portolani et al., 2001; 
Portolani et al., 2005; Portolani 
et al., 2006). It is worth noth-
ing that HHV-6 is frequently 
detected from healthy brain 
tissue as well (Challoner et al., 
1995; Chan et al., 2001; Hem-
ling et al., 2003). The CNS 
complications of HHV-6 infec-
tion, febrile seizures and en-
cephalitis, are discussed be-
low.
HHV-6 and febrile seizures
Febrile seizures are the most 
common cause of seizures in 
early childhood and more than 
80% of the patients with fe-
brile seizures are less than 
three years of age (Nelson and 
Ellenberg, 1978). ES was linked 
to febrile seizures long before 
HHV-6 was found (Möller, 
1956). After the discovery of 
HHV-6 and development in vi-
rological methods the associa-
tion of HHV-6 and febrile sei-
zures has strengthened, 
although the association is not 
indisputable (Zerr et al., 
2005b). The incidence of fe-
brile seizures in primary 
HHV-6 infection has been re-
ported to be 8% in Japanese 
(Asano et al., 1994) and 13% 
in U.S. populations (Hall et al., 
1994). 
HHV-6 encephalitis
The brain is an important site 
for both active and latent in-
fection of HHV-6. Indeed, se-
vere diseases of the brain have 
been reported, both during pri-
mary infection (Asano et al., 
1992; Kamei et al., 1997; Ahti-
luoto et al., 2000; Rantala et 
al., 2000; Kato et al., 2003; 
Mannonen et al., 2007) and 
during reactivation (Portolani 
et al., 2002; Isaacson et al., 
2005; Holden and Vas, 2007). 
Most of the cases are reported 
in immunocompromised pa-
tients, but cases are reported 
in immunocompetent subjects 
as well (Novoa et al., 1997; 
Portolani et al., 2002; Isaacson 
et al., 2005; Sawada et al., 
2007). Encephalitis or enceph-
alopathy is the most common 
clinical manifestation of HHV-6 
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infection after stem cell or 
bone marrow transplantation 
(Ljungman and Singh 2006). 
In solid organ transplantation 
HHV-6 infections are not as 
frequent as in stem cell or 
bone marrow transplantation; 
however, encephalitis or en-
cephalopathy is the second 
most common manifestation 
after fever and/or rash (Ljung-
man and Singh 2006). In some 
cases, HHV-6 encephalitis has 
been successfully treated with 
antivirals (Mookerjee and Vo-
gelsang, 1997; Rieux et al., 
1998; Johnston et al., 1999; 
Paterson et al., 1999; Yoshida 
et al., 2002).
HHV-6 and multiple sclerosis
Multiple sclerosis is a chronic 
inflammatory disease of the 
CNS. The exact etiology has re-
mained unknown but probably 
the disease develops as a result 
of the interplay between genetic 
and environmental factors. Sev-
eral lines of evidence have sug-
gested that infections, most 
probably virus infections, might 
act as environmental factors. 
Many viruses and other micro-
bial agents have been suspected 
but all have failed to stand the 
test of time. Probably the most 
promising candidate is HHV-6. 
Preliminary reports in the early 
1990s suggested possible in-
volvement of HHV-6 in the 
pathogenesis of MS. Sola and 
co-workers (1993) investigated 
serum antibody titers by IFA 
and viral DNA in PBMCs by 
PCR from 126 MS patients and 
from 500 controls. MS patients 
had significantly higher serum 
antibody titers than controls 
did. Anyhow, HHV-6 DNA was 
found only rarely from MS pa-
tients or controls and they con-
cluded that high serum HHV-6 
antibody titers might be a con-
sequence of immune impair-
ment rather than HHV-6 reacti-
vation of a latent HHV-6 
infection. On the other hand, it 
is known that HHV-6 DNA can 
be detected only within a nar-
row time window after active 
infection, and thus might in 
part reduce the amount of posi-
tive DNA findings in this study. 
In another study (Wilborn et 
al., 1994) HHV-6 DNA was de-
tected in three cerebrospinal 
fluid (CSF) samples of 21 MS 
patients (14.3%), but not in 
patients with other neurological 
diseases (OND) including myal-
gic encephalitis, meningitis and 
chronic fatigue syndrome or in 
controls. HHV-6 serum anti-
body titers investigated by ELI-
SA were also higher in sera of 
patients with MS compared to 
OND or controls, supporting 
possible involvement of HHV-6 
in the pathogenesis of MS. 
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For the first time direct evi-
dence to the involvement of 
HHV-6 in the pathogenesis of 
MS was reported in 1995 (Chal-
loner et al., 1995). Challoner 
and co-workers used represen-
tational difference analysis 
(RDA), introduced by Lisitsyn 
et al. (1993), a method that can 
be used to identify nucleic acid 
sequences that are unique to or 
present in greater numbers in 
diseased compared to healthy 
tissue. The DNA content from 
MS brain tissue was compared 
to DNA from peripheral blood 
leukocytes of healthy donors. 
By RDA they were able to iden-
tify a DNA sequence of 341 bp 
in size from one out of five pa-
tients that was essentially iden-
tical to the HHV-6 gene encod-
ing HHV-6 major DNA protein. 
Secondly, they studied the pres-
ence of HHV-6 DNA in brain 
samples by nested PCR and 
found that HHV-6 DNA was 
present in 78% and 74% of MS 
cases and controls, respectively. 
Although the authors of the pa-
per concluded that HHV-6, es-
pecially variant B is a commen-
sal virus in the human brain, 
they also demonstrated HHV-6B 
antigen expression in MS 
plaques in oligodendrocytes, 
but neither in control brains 
nor in the regions other than 
plaques in diseased brains. 
Since the destruction of oligo-
dendrocytes (leading to degra-
dation of myelin) is a hallmark 
of MS, the studies suggested an 
association of HHV-6 with the 
etiology or pathogenesis of MS. 
In another study (Cermelli et 
al., 2003), MS plaques were 
isolated by laser microdissec-
tion from brain samples and 
DNA was purified and used for 
detection of HHV-6 DNA by 
nested PCR. Controls included 
brain samples from normal ap-
pearing white matter (NAWM) 
from the same patients with MS 
and brain samples from pa-
tients with other neurological 
diseases and patients without 
known neurological disorders. 
The rate of HHV-6 DNA was 
similar in NAWM samples and 
in control patient samples, but 
was significantly higher in MS 
plaques. Others have studied 
HHV-6 antigen expression in 
MS brain samples as well. Car-
rigan and Knox with others 
(Carrigan and Knox, 1997; 
Knox et al., 2000) found HHV-6 
antigen in eight out of 11 brain 
samples from patients with MS 
but not in any of the seven con-
trol brain samples. The result 
was confirmed by Friedman et 
al. (1999), but Coates and Bell 
(1998) were not able to identify 
HHV-6 antigen in any of the 23 
brain samples from patients 
with MS; albeit the successfull 
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identification of HHV-6 antigen 
in salivary gland tissue.
Many other infectious agents 
have been associated with MS. 
Many of them have not stood 
the test of time. Two other her-
pesviruses VZV (Sotelo et al., 
2008) and EBV have been also 
associated with MS. Nearly 
100% of patients with MS are 
seropositive for EBV compared 
with 90-95% in adults (Sund-
strom et al., 2004; Levin et al., 
2005). Furthermore, individuals 
with a history of symptomatic 
EBV infection have a two-fold 
higher risk to develop MS com-
pared to individuals with as-
ymptomatic infection (Thacker 
et al., 2006; Nielsen et al., 
2007). In addition, human en-
dogenous retrovirus (HERV), 
MS-associated retrovirus, has 
been associated with the dis-
ease (Mameli et al., 2007).
Increased antibody titers in se-
rum to HHV-6 reported by Sola 
et al. (1993) have been also 
confirmed by other investiga-
tors (Wilborn et al., 1994). 
Anyhow, antibody findings in 
both serum and CSF summa-
rized in Table 2 are controver-
sial. 
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Table 2. Detection of HHV-6 antibodies in patients with MS compared to control patients
Sample Reference MS (%) Control (%)
Serum IgG (Sola et al., 1993) 71 41
(Wilborn et al., 1994) high titers low titers
(Liedtke et al., 1995) 39 18
(Nielsen et al., 1997) equal titers equal titers
(Soldan et al., 1997) 85 72
(Ablashi et al., 1998) 69 28
(Enbom et al., 1999) 100 100
(Ongradi et al., 1999) higher titers lower titers
(Ablashi et al., 2000) 90 75
(Taus et al., 2000) 30 25
(Xu et al., 2002) equal titers equal titers
(Derfuss et al., 2005) 84 88
II 100, higher titers (6A)30, equal titers (6B)
69, lower titers (6A)
38, equal titers (6B)
(Kuusisto et al., 2008) 88 86
Serum IgM (Liedtke et al., 1995) 3 2
(Soldan et al., 1997) 73 18
(Ablashi et al., 1998) 56 19
(Friedman et al., 1999) 80 16
(Ongradi et al., 1999) higher titers lower titers
(Ablashi et al., 2000) 71 15
(Enbom et al., 2000) 2 NT
(Taus et al., 2000) 0 0
(Xu et al., 2002) equal titers equal titers
(Kuusisto et al., 2008) 6 0
CSF IgG (Sola et al., 1993) 7 NT
(Wilborn et al., 1994) 0 0
(Ablashi et al., 1998) 39 7
(Friedman et al., 1999) 94 100
(Ongradi et al., 1999) 43 (6A)87 (6B)
17 (6A)
0 (6B)
(Ablashi et al., 2000) 4 NT
(Derfuss et al., 2005) 34 12
II 15 (6A)0 (6B)
0 (6A)
0 (6B)
(Kuusisto et al., 2008) 0 0
CSF IgM (Friedman et al., 1999) 0 0
(Ongradi et al., 1999) 0 (6A)57 (6B)
0 (6A)
0 (6B)
(Ablashi et al., 2000) 0 0
(Kuusisto et al., 2008) 0 0
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HHV-6 DNA findings in differ-
ent sample materials from pa-
tients with MS compared to 
different controls vary between 
studies as well (Table 3). DNA 
detection rates vary from 0 to 
83% and 0 to 53% in serum in 
cases and controls, respective-
ly. In CSF the detection rates 
are from 0 to 78% and 0 to 
20% in cases and controls, re-
spectively. Only a few studies 
have reached a statistically sig-
nificant difference between 
groups. In brain samples the 
detection rates are higher than 
in serum or CSF, although only 
a slight increase in positive 
cases are seen in MS compared 
to controls. 
Still, to date, only few studies 
have evaluated the possible 
mechanisms by which HHV-6 
might be involved in the 
pathogenesis of MS, albeit 
many reviews exist (Clark, 
2004). It has been postulated 
that HHV-6 might induce a 
phenomenon known as molec-
ular mimicry (Fotheringham 
and Jacobson, 2005). The resi-
dues 4-10 from HHV-6 U24 
gene-encoded hypothetical 
protein are identical to myelin 
basic protein residues 96-102 
(Tejada-Simon et al., 2003). In 
addition, the synthetic peptide 
corresponding residues 1-13 of 
U24 was able to induce activa-
tion in more than 50% of the 
T-cells recognizing myelin ba-
sic protein residues 93-105. 
The frequency of the subpopu-
lation of T-cells recognizing 
both peptides was significantly 
increased in patients with MS 
compared to healthy controls. 
38  I HHV-6 IN MS & ENCEPHALITIS
REVIEW OF THE LITERATURE
Table 3. Detection of HHV-6 DNA in patients with MS compared to control patients
Sample Reference MS (%) Control (%)
Serum DNA (Wilborn et al., 1994) 0 0
(Martin et al., 1997) 0 NT
(Soldan et al., 1997) 30 0
(Fillet et al., 1998) 6 0
(Goldberg et al., 1999) 4 0
(Mirandola et al., 1999) 0 0
(Tejada-Simon et al., 2002) 67 33
(Al-Shammari et al., 2003) 0 0
(Tejada-Simon et al., 2003) 83 55
II 0 0
(Kuusisto et al., 2008) 0 0
PBMC DNA (Sola et al., 1993) 3 4
(Torelli et al., 1995) 3 22
(Merelli et al., 1997) 5 0
(Mayne et al., 1998) 25 24
(Rotola et al., 1999) 41 29
(Ablashi et al., 2000) 75 60
(Hay and Tenser, 2000) 7 14
(Kim et al., 2000) 21 0
(Rotola et al., 2000) 40 37
(Taus et al., 2000) 14 0
(Chapenko et al., 2003) 62 29
Plasma DNA (Chapenko et al., 2003) 31 0
CSF DNA (Wilborn et al., 1994) 14 0
(Liedtke et al., 1995) 11 5
(Martin et al., 1997) 0 0
(Ablashi et al., 1998) 17 0
(Fillet et al., 1998) 6 0
(Enbom et al., 1999) 6 6
(Goldberg et al., 1999) 0 0
(Mirandola et al., 1999) 0 0
(Taus et al., 2000) 0 0
(Tejada-Simon et al., 2002) 47 20
(Cirone et al., 2002) 78 NT
II 0 0
(Kuusisto et al., 2008) 0 0
Brain DNA (Challoner et al., 1995) 78 74
(Sanders et al., 1996) 57 38
(Merelli et al., 1997) 0 50
(Coates and Bell, 1998) equal levels equal levels
(Friedman et al., 1999) 36 14
Hemgling et al., (2003) NT 88
(Cermelli et al., 2003) 58 27
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HHV-6 and epilepsy
CNS infections have been as-
sociated with epilepsy. Dr. Ue-
sugi with others (2000) was 
the first to suggest that HHV-6 
might be a cause of temporal 
lobe epilepsy. They found that 
6 out of 16 (35%) temporal 
lobe resections were positive 
for HHV-6. In another study, 
HHV-6 was found in 4 out of 8 
mesial temporal lobe resec-
tions, but not in any of the 7 
neocortical epilepsy brain 
samples (Donati et al., 2003). 
HHV-6 was identified to be 
variant B in all of the cases 
and infected cells were shown 
by immunohistochemistry to 
be GFAP-positive astrocytes. In 
subsequent studies the investi-
gators studied 16 patients more 
and found that 11 of these 
(69%) were positive for HHV-
6B (Fotheringham et al., 2007). 
They were able to isolate pri-
mary astrocytes and culture 
them in vitro, and found that 
the astrocytes expressed HHV-6 
antigen and were HHV-6B 
DNA positive. Furthermore, 
they infected astrocyte cultures 
with HHV-6B and showed that 
infection resulted as glutamate 
transporter dysfunction provid-
ing a possible mechanism for 
the induction of mesial tempo-
ral lobe epilepsy symptoms 
(Fotheringham et al., 2008). 
HHV-6 in 
immunocompromised 
patients
HHV-6 in AIDS
HHV-6, especially HHV-6A, has 
been suggested to play a part 
in AIDS as a cofactor or a pro-
gression factor (Lusso and 
Gallo, 1994; Lusso and Gallo, 
1995). HHV-6 and HIV-1 have 
a tropism for CD4+ T cells 
(Lusso et al., 1988; Lusso et 
al., 1989) and HHV-6 might 
partially contribute to the loss 
of these cells. Furthermore, 
HHV-6 is capable of transacti-
vating the HIV-1 LTR promoter 
thus stimulating HIV-1 infec-
tion (Ensoli et al., 1989; McCa-
rthy et al., 1998). HHV-6 might 
indirectly enhance HIV infec-
tion by promoting secretion of 
cytokines that are known to 
enhance HIV infection, i.e. 
interleukin-1β and tumor ne-
crosis factor-α (Flamand et al., 
1991). HIV uses the receptor 
complex formed by CD4 and 
chemokine receptor CCR5 or 
CXCR4. Interestingly, HHV-6 
infection in lymphoid tissues 
ex vivo suppresses CCR5-tropic 
HIV-1 infection, but not CX-
CR4-tropic HIV-1 (Grivel et al., 
2001). This might lead to HIV 
infection through CXCR4 co-
receptor which is linked to 
more aggressive progression of 
HIV infection to AIDS. In ma-
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caques (Macaca nemestrina) 
co-infection by HHV-6A and 
simian immunodeficiency vi-
rus (SIV) results in accelerated 
progression of AIDS accompa-
nied with depletion of both 
CD4+ and CD8+ T cells (Lusso 
et al., 2007).
HHV-6 in transplantation
HHV-6 infection is frequently 
detected in immunosuppressed 
patients and in most cases the 
infection is HHV-6B reactiva-
tion (Drobyski et al., 1993; 
Wang et al., 1999). The inci-
dence peaks at two to three 
weeks after transplantation 
(Singh and Carrigan, 1996). 
The incidence of HHV-6 infec-
tion varies greatly between 
studies and is 28 to 75% for 
bone marrow transplant recipi-
ents and 0 to 85% for solid or-
gan transplant recipients (De 
Bolle et al., 2005a). HHV-6 in-
duced encephalitis and en-
cephalopathy are the most 
common clinical diseases after 
stem cell or bone marrow 
transplantation (Drobyski et 
al., 1994; Wang et al., 1999; 
Yoshida et al., 2002) following 
pneumonitis (Carrigan et al., 
1991; Cone et al., 1993) and 
delayed engraftment (Johnston 
et al., 1999). There are reports 
on rash development (Yoshika-
wa et al., 1991), bone marrow 
suppression (Carrigan and 
Knox, 1994; Hentrich et al., 
2005), and graft versus host 
disease (GVHD) (Appleton et 
al., 1995; Hentrich et al., 2005; 
Zerr et al., 2005a). In liver 
transplantation, clinical mani-
festations of HHV-6 infection 
include fever and/or rash, en-
cephalitis or encephalopathy 
(Sutherland et al., 1991; Mon-
tejo et al., 2002), hepatitis 
(Ward et al., 1989; Humar et 
al., 2002), graft dysfunction or 
rejection (Okuno et al., 1990; 
Lautenschlager et al., 1998; 
Griffiths et al., 1999; Lauten-
schlager et al., 2000), and 
bone marrow suppression or 
pneumonitis (Singh et al., 
1997). In addition, HHV-6B 
can infect gastroduodenal mu-
cosa after liver transplantation 
(Halme et al., 2008). HHV-6B 
has been shown to infect kid-
ney transplants as well (Hel-
anterä et al., 2008).
HHV-6 transmission
HHV-6B is probably in most 
cases transmitted horizontally 
via saliva from parents or sib-
lings to the child (Mukai et al., 
1994; Di Luca et al., 1995; van 
Loon et al., 1995; Tanaka-Taya 
et al., 1996; Pereira et al., 
2004). Virtually all of the iso-
lates from the saliva have been 
variant B (Collot et al., 2002) 
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which might suggest that HHV-
6A is not transmitted through 
saliva. In addition, vertical 
transmission by congenital in-
fection occurs in approximately 
1-2% of the cases. Congenital 
infection may occur either by 
virus crossing the placenta or 
may be hereditary if virus is in-
tegrated into human chromo-
somes (Ward, 2005). As men-
tioned earlier in the Structure 
and genome section HHV-6 
contains an array of sequences 
similar to those present in te-
lomers of mammalian chromo-
somes (Gompels and Macaulay, 
1995; Gompels et al., 1995). 
Although the exact role of these 
telomeric repeats at the DRs is 
not known, it has been sug-
gested that they might be in-
volved in site-specific integra-
tion of the HHV-6 genome to 
the site near chromosomal te-
lomers in mammalian genome 
(Torelli et al., 1995; Daibata et 
al., 1998). Interestingly, HHV-6 
encodes a protein that has sig-
nificant homology to adeno-as-
sociated virus (AAV) rep protein 
(Thomson et al., 1991) which 
has a role in the integration of 
the AAV to the host genome 
(Linden et al., 1996). Thus it is 
assumed that HHV-6 AAV rep 
homology protein might pos-
sess similar functions in the in-
tegration of HHV-6 into the host 
genome (Ward, 2005). 
Congenital infection detected 
as DNA in cord blood cells has 
been reported in 1.6% of Ger-
man births (Adams et al., 
1998) and 0.9% of Swedish 
births (Dahl et al., 1999). In-
terestingly, it has been pub-
lished that in 0.2% of Japanese 
births HHV-6 was transmitted 
from either of the parents to 
the child (Tanaka-Taya et al., 
2004). In another study, Ward 
and others (2007) identified 
chromosomally integrated 
HHV-6 in 1.3% of older chil-
dren and adults. The percent-
age of adults having HHV-6 
genome integrated into their 
genomes is approximately in 
the same order as the percent-
age of congenital infections 
suggesting that most congeni-
tal infections might occur by 
inheritance rather than virus 
crossing through placenta. Al-
though one report describes 
severe neurological symptoms 
related to intrauterine trans-
mission (Lanari et al., 2003), 
most of the intrauterine trans-
missions does not cause signif-
icant risk (Boutolleau et al., 
2003; Hall et al., 2004). HHV-6 
DNA has been found in genital 
tract of approximately 20% or 
less of pregnant women (Oku-
no et al., 1995; Maeda et al., 
1997; Ohashi et al., 2001; Ca-
serta et al., 2007), but perina-
tal transmission seems unlike-
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ly. The common transmission 
route among young children, 
fecal-oral, has not been docu-
mented in the case of HHV-6, 
although HHV-6 has been re-
ported to be excreted into stool 
persistently or intermittently 
(Suga et al., 1995; Suga et al., 
1998). Despite the fact that 
virtually all postnatal HHV-6 
infections in young children 
are caused by HHV-6B (Dew-
hurst et al., 1993a) as much as 
one third of all congenital in-
fections are caused by HHV-6A 
(Hall et al., 2004).
Antiviral susceptibility
Unfortunately, to date no con-
trolled clinical trials of antiviral 
activity against HHV-6 have 
been carried out (Clark and 
Griffiths, 2003; De Bolle et al., 
2005a) and no drugs have been 
formally approved for the treat-
ment of HHV-6 infections. In 
general, antiviral compounds 
effective against another beta-
herpesvirus, CMV, show simi-
lar potency against HHV-6 in 
vitro. Therefore, the drugs 
clinically used are the same 
that are used for the treatment 
of HCMV infections. The drugs 
that are potentially effective 
against HHV-6, namely ganci-
clovir, foscarnet and cidofovir, 
all have their side effects and 
should not be, unless in life-
threatening situations, used for 
the treatment of immunocom-
petent patients. 
In vitro, ganciclovir, a guanine 
analogue, has superior activity 
against HHV-6 compared to 
acyclovir or penciclovir that is 
independent of the propaga-
tion system used (Burns and 
Sandford, 1990; Agut et al., 
1991; Yoshida et al., 1998; 
Manichanh et al., 2000). The 
pyrophosphate analogue fos-
carnet, and phosphonate cido-
fovir have both been shown to 
have antiviral activity against 
HHV-6 (Agut et al., 1991; Rey-
men et al., 1995). HHV-6 lacks 
a viral thymidine kinase and 
therefore thymidine kinase-de-
pendent drugs such as acyclo-
vir have little or no effect 
against HHV-6 in vitro (Agut et 
al., 1991; Reymen et al., 
1995).
In vivo several case reports 
have showed that ganciclovir 
is effective against HHV-6 en-
cephalitis in patients who un-
derwent bone marrow or solid 
organ transplantation (Mook-
erjee and Vogelsang, 1997; 
Rieux et al., 1998; Johnston et 
al., 1999; Paterson et al., 1999; 
Yoshida et al., 2002). In few 
cases the treatment with gan-
ciclovir has shown no response 
(Tiacci et al., 2000; Rossi et 
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al., 2001). Interestingly, the 
case presented by Rossi et al. 
(2001) appeared to be a prima-
ry HHV-6A infection of an 
adult woman and this might 
have affected the outcome. Al-
though lacking in vitro antivi-
ral activity, acyclovir in high 
doses reduced the proportion 
of HHV-6 DNA-positive blood 
samples in bone marrow trans-
plant patients and tended to 
lower the HHV-6 DNA levels 
compared to those who were 
not treated with the drug 
(Wang et al., 1996). 
Viral neurological infections
Viral infections of the CNS oc-
cur worldwide and are most 
prevalent in young ages (Kosk-
iniemi et al., 1991; Koskiniemi 
et al., 2001). Inclusion of con-
ventional childhood viruses, 
such as measles, mumps and 
rubella into the vaccination 
program in Finland in 1982 
has changed the spectrum of 
the causative agents of viral 
encephalitis. The emergence of 
new viruses or new virus 
strains will change our view 
even more in the future, not to 
mention development of more 
sensitive molecular diagnostic 
methodology. VZV and entero-
viruses seem to be the most 
common causes of various 
CNS infections following her-
pes simplex viruses in Finland 
(Figure 5) (Koskiniemi et al., 
2001; Kupila et al., 2006). En-
teroviruses are the most com-
mon cause of aseptic meningi-
tis (Kupila et al., 2006). 
Encephalitis, meningitis, my-
elitis, vasculopathy, ganglion-
euritis, retinal necrosis and 
optic neuritis can be caused by 
one or more members of the 
HHV family (Gilden et al., 
2007) and jointly the family 
comprises more than half of 
identified pathogens in viral 
CNS infections (Koskiniemi et 
al., 2001). 
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Multiple sclerosis
Multiple sclerosis (MS) is the 
most common neurological 
cause of disability in young 
adults. 
Pathogenesis
MS is a chronic demyelinating 
disease of the CNS with un-
known etiology. The disease is 
most probably caused by inter-
play between genes and envi-
ronmental factor(s). Certain 
genes probably increase the 
risk of developing MS, but en-
vironmental factors trigger the 
development and cause relaps-
es, typical of MS. Anyhow, epi-
demiological and immigration 
studies have suggested that not 
only genetic factors increase 
the risk, but also environmen-
tal factors, including viruses 
might increase risk to develop 
the disease (Kurtzke, 1993).
The mechanisms of demyelina-
tion, the primary feature of 
MS, are heterogeneous and 
vary between patients. The ax-
ons are relatively conserved 
during the disease, but the 
axon potentials, electrical com-
munication system between 
neurons, are transmitted insuf-
Figure 5. Proportions of findings (confirmed or probable) to different 
viruses among patients with CNS infection in Finland. *Only selected 
samples were studied. (Koskiniemi et al., 2001)
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ficiently, because of lack of 
myelin (Lassmann et al., 2001). 
Myelin is a protein component 
produced by brain supporter 
cells, oligodendrocytes (Figure 
6). In normal myelinated tracts 
most axons are wrapped by 
myelin sheaths made from lay-
ers of cell membrane. One oli-
godendrocyte can contribute 
up to 40 myelin sheaths to 
nearby axons (ffrench-Con-
stant, 1994). 
Proteolytic activation has been 
associated with demyelination 
process in multiple sclerosis. 
Matrix metalloproteinases 
(MMPs) and plasminogen acti-
vators have been shown to be 
both beneficial as well as det-
rimental enzymes within the 
CNS taking part in both physi-
ological and pathophysiologi-
cal processes (Teesalu et al., 
2002; Agrawal et al., 2008). El-
evated levels of tissue plasmi-
nogen activator (tPA) have 
been reported in MS CSF (Ak-
enami et al., 1996). In experi-
mental autoimmune encepha-
lomyelitis (EAE), a widely 
used animal model for MS, ac-
tivation of MMPs and plasmi-
nogen activators have been re-
ported (Teesalu et al., 2001).
Figure 6. Oligodendrocytes produce myelin, which is composed of mul-
tiple layers of oligodendrocyte membranes that wrap concentrically 
around one or more axons. The myelin sheath around an axon acts like 
an electrical insulator, allowing nerve impulses to be conducted very 
quickly. Myelin appears white and shiny because the layers of membrane 
that form it contain large amounts of lipids (ffrench-Constant, 1994).
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There are at least four different 
pathogenetic mechanisms of 
MS that can be identified from 
pathology of brain samples 
causing MS (Lassmann et al., 
2001). The mechanisms are 
presented in Figure 7. The first 
step in all four mechanisms is 
inflammation, caused by T-
cells and macrophages, which 
can lead by four different ways 
to either demyelination or to 
programmed cell death, apop-
tosis, of oligodendrocytes. In 
the first pattern the mac-
rophages mediate demyelina-
tion and induce the release of 
cytokines, such as tumor ne-
crosis factor α (TNF-α), reac-
tive oxygen intermediates 
(ROI) and proteinases. In the 
second pattern antibodies 
Figure 7. Different pathogenetic mechanisms involved in the formation 
of MS lesions. Green spheres represent normal myelin sheaths and yel-
low spheres demyelinated myelin sheaths produced oligodendrocytes 
(OG). Y, antibody, C, Complement, Th1, T-helper cell 1, Th2, T-helper cell 
2, Tc1, cytotoxic T cell 1 (Lassmann et al., 2001).
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raised against the myelin oligo-
dendrocyte unit, such as anti-
myelin oligodendrocyte glyco-
protein (anti-MOG) and 
anti-galactocerebroside (anti-
GC) cause demyelination. The 
third pattern is caused by dif-
ferent toxins, or ischemia, or 
by infection of viruses. These 
lead to apoptosis of oligoden-
drocytes. The fourth pattern is 
caused by deficiency in oligo-
dendrocyte metabolic pathways 
as a result of macrophage tox-
ins or a genetic defect.
B-cells and humoral immune 
response in multiple sclerosis
MS is predominantly consid-
ered a T-cell mediated disease 
due to the fact that MS plaques 
contain large amounts of T-
cells. However, B-cells have 
gathered considerable impact 
in the pathogenesis recently. 
Indeed, B-cells might contrib-
ute to the pathogenesis at 
many levels starting from the 
earliest antigen capture, the 
processes of tissue destruction, 
and even continuing in remy-
elination and tissue repair 
(Duddy and Bar-Or, 2006).  
One of the features of the 
pathogenesis of MS is the pro-
duction of chronic intrathecal 
immunoglobulins (Ig) present-
ing as oligoclonal IgG bands 
(OCB) in cerebrospinal fluid. 
The clonality of the IgG in 
brain and CSF seems to be sta-
ble over long periods in MS 
(Walsh and Tourtellotte 1986). 
Anyhow, it has been shown 
that the prevalence of MS pa-
tients with positive OCBs in-
crease over time suggesting 
that activated B-cells in early 
disease are not yet residents of 
the CNS (Petereit and Reske 
2005). In addition, there are a 
number of low-affinity IgGs 
present in CSF towards various 
infectious agents, such as 
measles, rubella, VZV and 
Chlamydia pneumoniae (Sin-
dic et al., 1994; Luxton et al., 
1995; Reiber et al., 1998; Der-
fuss et al., 2001). Low-affinity 
IgGs present in CSF as well as 
in serum in similar patterns. 
Low-affinity IgGs are hypothe-
sized to be part of polyclonal 
B-cell activation (Derfuss et 
al., 2001). However, polyclonal 
B-cell activation, per se, is not 
sufficient to produce OCBs. 
The specificity of the OCBs is 
not known.
It has been suggested that if 
virus(es) cause MS, it should 
be possible to demonstrate that 
OCBs contain IgG bands that 
are directed to a given virus 
(Gilden, 2001). However, due 
to the heterogeneity of MS it is 
not likely to find a single virus 
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that causes all of the MS cases. 
Indeed, it has been shown that 
some of the patients with MS 
have OCBs that are directed 
against EBV. Rand et al. (2000) 
showed that one third of the 
15 patients with MS had OCBs 
directed against EBNA-1 in 
their CSF, although critically 
analyzing the results only two 
patients had CNS-specific 
OCBs directed against EBV, 
since other three had similar 
bands in their serum as well. 
In another study two EBV pro-
teins were shown to react with 
OCBs (Cepok et al., 2005). In 
addition, measles antigen 
might react with OCBs as well 
(Vandvik et al., 1976). 
Epidemiology
The geographic distribution 
of MS is unique, the disease 
being more common in tem-
perate zones than near the 
equator. MS is most common 
in populations of Northern Eu-
rope descent, especially in 
Scandinavia, the British Isles, 
the Northern regions of the 
United States and Southern 
Canada (Compston, 1997), and 
it has even been postulated 
that Vikings might have been 
the ancestor in dissemination 
of the genetic susceptibility to 
the disease (Poser, 1994; Poser, 
1995). Anyhow, genetic sus-
ceptibility cannot exclusively 
explain the uneven geographi-
cal distribution, suggesting the 
involvement of environmental 
factors in the onset of the dis-
ease. Large-scale immigrant 
studies have shown that the 
risk of MS decreases if children 
migrates from a high- to low-
risk region and increases when 
children migrates from a low- 
to high-risk region, in contrast 
to rates for nonmigrants at 
their birthplaces (Kurtzke, 
1993). In generally, this applies 
to children under the age of 
14. Immigrants older than 15 
years have already acquired 
the risk from the homeland. 
These studies suggest that en-
vironmental factors are as im-
portant factors as genetic sus-
ceptibility in the development 
of the disease. Finland belongs 
to a high-risk area of MS with 
a prevalence of approximately 
100/100000 (Sumelahti et al., 
2002). MS cases seem to clus-
ter to the Western part of Fin-
land and approximately a two 
times higher prevalence com-
pared to the national average 
has been reported in Seinäjoki 
in Southern Ostrobothnia (Su-
melahti et al., 2001). 
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The aims of the present PhD 
studies were to investigate 
neurological infections possi-
bly associated with HHV-6. 
This virus has been associated 
with MS and a major goal was 
to clarify the role of HHV-6 in 
the pathogenesis of MS. The 
itemized aims were as follows:
1. To study the HHV-6 antigen 
expression in multiple sclero-
sis brain tissue and compare 
it to brain tissue obtained 
from healthy controls. Fur-
thermore, we aimed to study 
the expression of tPA, an 
enzyme implicated in the 
demyelination process in 
MS, in relation to the expres-
sion of HHV-6 antigen.
2. To study the serological evi-
dence of the role of HHV-6 in 
the development of MS and 
measure HHV-6 antibodies 
in serum and CSF samples 
from patients with MS and 
compare the levels with 
patients with OND.
3. To study the presence of 
oligoclonal bands in patients 
with MS and serologically 
suspected HHV-6 infection 
and the specificity of OCBs 
in regard to HHV-6 antigen.
4. To study the relationship 
between HHV-6 primary 
infection and neurological 
symptoms in children with 
suspected encephalitis.
Aims of  
 the study
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Patients, samples 
and controls (I-IV)
Samples used in studies I-IV 
are presented in Table 4. Brain 
tissue specimens from chronic 
plaques of the patients with 
MS and control brain tissue 
specimens were acquired 
through Professor John 
Zabriskie from Rockefeller Uni-
versity, New York, NY, USA. 
All of the brain specimens 
were from U.S. patients. Serum 
and CSF samples from patients 
with MS and patients with 
OND were collected from the 
Neurological Outpatient De-
partment of Helsinki University 
Central Hospital during the 
years 2003 and 2004. Serum 
was separated from the whole 
blood and CSF samples were 
centrifuged at 2700 g for 10 
minutes to obtain cell-free CSF. 
All samples were aliquoted, 
frozen and stored at -70 oC un-
til used. The total number of 
patients was 126. In a retro-
spective patient analysis 27 
appeared to have a clinically 
definite MS (CDMS), diagnosed 
using the McDonald criteria 
(McDonald et al., 2001) revised 
by Polman et al. (2005). 19 pa-
tients had clinically possible 
MS (CPMS). Reference patients 
group was formed from pa-
tients with various other neu-
rological diseases and symp-
toms (OND) with matching 
gender and ages (± 5 yrs) to 
each patient with CDMS. A to-
tal of 46 patients with MS (ei-
ther CDMS or CPMS) and ref-
erence group of 27 patients 
with OND were included in the 
Table 4. Samples used in studies I-IV
Study I II III IV
Brain tissue 15 (MS)10 (controls) - - -
Serum -
27 (CDMS)
19 (CPMS)
26 (OND)
*4 (CDMS)
5 (CPMS)
53 (suspected 
encephalitis)
CSF -
27 (CDMS)
19 (CPMS)
27 (OND)
4 (CDMS)
5 (CPMS)
**4 (suspected 
encephalitis)
*patients with positive HHV-6 IgG CSF or patients with low-avidity antibodies in 
serum in study II were enrolled to study III, **only CSF samples corresponding 
HHV-6 low-avidity IgG serum samples were studied
materials and 
 methods
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studies. One serum sample 
from patient with OND was 
not available. Otherwise serum 
and CSF samples were avail-
able from all of the patients 
with CDMS, CPMS, and OND. 
All patients gave a written 
consent and the Ethics Com-
mittee of Helsinki University 
and Helsinki University Central 
Hospital approved the study. 
Sera of 53 children less than 
15 years old were collected 
from a panel sent to the De-
partment of Virology, Universi-
ty of Helsinki, for suspected 
viral encephalitis. The prospec-
tive study covered more than 
two thirds of the whole coun-
try and lasted for a two-year 
period 1995–1996 (Koskiniemi 
et al., 2001). The samples for 
the study of HHV-6 were con-
secutively collected from the 
first and last quarter of the 
year 1995.
Immunohistochemistry and 
in situ hybridization (I)
Immunohistochemical staining 
and in situ hybridization were 
carried out using automatic 
slide stainers Ventana Gen IITM 
and Ventana DiscoveryTM (Ven-
tana Medical Systems Inc., 
Tucson, AZ, USA). Brain tissue 
specimens from MS plaques of 
15 patients and from respec-
tive areas of ten controls were 
fixed in formalin and embed-
ded in paraffin. Serial 6-μm 
sections were cut from the par-
affin blocks for immunohis-
tochemistry and 3-4-μm thick 
sections for in situ hybridiza-
tion. Viral antibodies used 
were: mouse monoclonal to 
HHV-6B virion protein 101 kDa 
(Pellett et al., 1993) (Chemicon 
International Inc, Temecula, 
CA, USA), HHV-6A gp200 
(Chemicon) and CMV clone 
CCH2 (DAKO, Carpinteria, CA, 
USA). Cell markers used were 
rabbit anti glial fibrillary acidic 
protein (GFAP) (DAKO) for as-
trocytes and rabbit anti myelin 
basic protein (MBP) (DAKO) 
for oligodendrocytes. 
Epstein-Barr in situ hybridiza-
tion was done using an FITC-
conjugated EBER PNA probe 
(DAKO). 
Immunofluorescence 
assays (II, IV) 
HHV-6A strain GS was grown 
in HSB-2 T-cell line and HHV-
6B strain Z-29 was grown in 
MOLT-3 T-cell line. Equal 
amount of infected cell super-
natant from previous infection 
and mixture of uninfected cells 
were mixed together. The final 
cell concentration was approxi-
mately 106 cells/ml. After the 
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infection fetal bovine serum 
concentration was lowered to 
2% or to 0.5%, in HHV-6A and 
HHV-6B infections, respective-
ly, and 5 µg/ml hydrocortisone 
was added. After six to ten 
days post infection cells were 
mixed with uninfected cells to 
achieve a proportion of infect-
ed cells of approximately 30 
per cent. Approximately 6 x 
104 cells per well were spotted 
on a 10-well (8-mm diameter) 
diagnostic glass slides and air-
dried. After fixation with ace-
tone the slides were stored at 
-20oC until used. Panels of 
known positive and negative 
sera were used to validate each 
patch of slides prepared.
Serum samples were diluted 
either two- or four-fold dilu-
tions in PBS and applied to 
wells. Slides were incubated 30 
min at 37oC and washed three 
times. Bound antibodies were 
detected with FITC-conjugated 
anti-human IgG secondary an-
tibody (Monosan, Uden, The 
Netherlands) and counter-
stained with Evan’s Blue. 
Avidity measurements (II, IV)
Avidity was determined using 
IFA method essentially as men-
tioned above with one addi-
tional step in which the bound 
antibodies from the serum 
were washed with 8 M urea to 
remove low-affinity antibodies. 
The end-point titer was com-
pared to one without urea 
wash and the avidity was cal-
culated using the following 
equations:
Measurement of intrathecal 
antibody production (II)
Serum HHV-6 IgG antibody ti-
ters were compared to the cor-
responding CSF HHV-6 IgG an-
tibody titers. Ratio below 20 
suggests ITAP (Levine et al., 
1978):
The antibody index (AbI) was 
used to determine CNS-based 
production of HHV-6 specific 
antibodies. The antibody ratio 
Equation (1) was used in study ii and equation (2) was used in study iv.
,marker of ITAP <20 (3)
! 
serumAb
CSFAb
 
,low-avidity >8 (1)
 ,low-avidity < 12.5% (2)
! 
avidity =
w /oUREA
wUREA
 
! 
avidity% =
wUREA
w /oUREA
"100% 
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between serum and CSF was 
corrected against total IgG 
amount in serum and CSF us-
ing the following equation:
Isoelectric focusing (IEF) 
and immunofixation (III)
Paired serum/CSF samples 
were diluted to the same IgG 
concentration (20 mg/L IgG) 
and 10 μl of sample was ap-
plied to isoelectric focusing. 
Samples were isoelectrically 
focused using Sebia Hydragel 
3 CSF Isofocusing system on 
the Sebia Hydrasys Focusing 
apparatus (Sebia, Lisses, 
France). IgG bands were local-
ized by immunofixation with 
peroxidase conjugated anti-IgG 
antiserum (Sebia) and visual-
ized using immunoperoxidase 
staining using reagents from 
Sebia.
Affinity-driven 
immunoblot (III)
Nitrocellulose membrane was 
coated with HHV-6A (Ad-
vanced Biotechnologies, Co-
lumbia, MD, USA), HHV-6B 
(Meridian Life Science, Saco, 
ME, USA) or sucrose gradient 
ultracentrifugation purified 
HSV-1 viral antigen for 30 min 
,>1.5 pathological finding (4) 
! 
AbI =
CSFAb
SAb
CSFIgG
SIgG
 
and non-specific binding sites 
were blocked with milk casein. 
The membrane was overlaid 
with isoelectrically-focused se-
rum/CSF samples in a thin 
agarose gel. Passive transfer 
with one kilogram weight was 
allowed to proceed for 30 min. 
Transferred bands were detect-
ed using alkaline-phosphatase 
conjugated anti human IgG 
(DAKO) and visualized using 
NBT/BCIP substrate solution. 
HSV-1 and mumps viral anti-
gens as well as casein-blocked 
membranes were used as con-
trols to ensure the specificity 
of the transferred IgG bands. 
DNA microarray (II)
DNA was extracted from 200 
µl of serum or CSF samples us-
ing High Pure Viral Nucleic 
Acid Kit (Roche Applied Sci-
ence, Basel, Switzerland). 
Multiplex-PCR and microarray 
was carried out as published 
(Jääskeläinen et al., 2006; 
Jääskeläinen et al., 2008). 
Briefly, two multiplex-PCR re-
actions were used; one to iden-
tify HSV-1 and HSV-2 and one 
to identify CMV, EBV, VZV, 
HHV-6A, HHV-6B and HHV-7 
viral sequences. The multiplex-
PCR products were pooled be-
fore transcribing into ssRNA 
using AmpliScribe™ T3-Flash™ 
Transcription Kit (Epicentre 
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Biotechnologies, Madison, WI, 
USA). The ssRNA samples 
were hybridized with specific 
oligonucleotide probes for each 
herpesvirus for 20 min at 42°C 
and microarray slides were 
washed. The primer extension 
was carried out with CY5-la-
beled nucleotides 20 min at 
52°C. After washing the mi-
croarrays were analyzed using 
a ScanArray Express scanner, 
and ScanArray™ and QuantAr-
ray™ software (Perkin-Elmer, 
Wellesley, MA, USA). Commer-
cial viral DNA samples were 
used as controls in each mi-
croarray experiment.
DNA extraction and 
variant-specific PCR (IV)
DNA was extracted from 200 
µL of CSF and serum samples, 
and eluted in 80 µL of DNase-
treated water. DNA was ex-
tracted using the QIAamp Viral 
RNA Mini Kit (QIAGEN, 
Hilden, Germany) according to 
the manufacturer’s instruc-
tions. Positive controls com-
prised of HHV-6A (strain 
U1102) and 6B (strain Z29) su-
pernatant. Primary and nested 
PCR for Major Capsid Protein 
(MCP) and Large Tegument 
Protein (LTP) were conducted 
as previously described (Sec-
chiero et al., 1995; Akhyani et 
al., 2000). Viral load was de-
termined by quantitative real-
time PCR as previously de-
scribed (Nitsche et al., 2001).
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Immunohistochemical and 
in situ hybridization analysis 
of MS brain samples (I)
HHV-6 variant B antigen ex-
pression was identified in 67% 
(10/15) brain samples from 
patients with MS. From ten 
control brain samples, three 
expressed HHV-6 antigen as 
well (p=0.07). All of the sam-
ples were negative for CMV. 
Our results were in line with 
other reports (Challoner et al., 
1995; Friedman et al., 1999). 
HHV-6 expression was identi-
fied mainly in oligodendro-
cytes, but also in astrocytes, 
macrophages and microglial 
cells, identified by cell markers 
using double staining tech-
niques. It seems that, although 
HHV-6 is a commensal in CNS, 
it is more prevalent in plaques 
that are involved in the demy-
elination process. Basically, the 
detection of HHV-6 antigen in 
brain sections suggests that 
HHV-6 is in an active replica-
tive form, not in a latent form. 
This might indicate that ac-
tively replicating HHV-6 is in-
volved in the plague formation 
in MS brains. 
Based on earlier obser-
vations that plasmino-
gen activation is associ-
ated with demyelination 
process, we studied the 
expression of tPA anti-
gen. tPA staining of the brain 
samples revealed that 7 out of 
15 MS brain samples expressed 
strongly tPA, but in all control 
samples tPA expression was 
only weak or moderate and re-
stricted to blood vessel walls 
(p=0.01). Furthermore, double 
staining with HHV-6 and tPA 
showed that of seven samples 
with high tPA expression five 
expressed HHV-6 antigen as 
well. In conclusion, five out of 
15 brain samples from patients 
with MS concomitantly ex-
pressed HHV-6 antigen and tPA 
compared to none of the brain 
samples from the control pa-
tients (p=0.04). It is possible 
that active HHV-6 infection in-
duces the expression of tPA in 
CNS. Another possibility is 
that tPA is an epiphenomenon 
related to inflammation nor-
mally observed within plaques. 
tPA is an important enzyme in 
neurogenesis and neuronal re-
modeling as well as in neu-
ronal degeneration (Teesalu et 
al., 2002; Teesalu et al., 2004). 
It affects the CNS in two ways: 
it activates a zymogen, plasmi-
nogen, to active protease plas-
min and tPA have also direct 
Results and 
 discussion
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effects in CNS. It have been 
suggested that tPA in moderate 
levels is physiologically benefi-
cial to CNS, but exaggerated 
levels of tPA could lead to tis-
sue damage (Teesalu et al., 
2002). In addition, tPA have 
been associated with neuro-
logical diseases such as MS 
showed by elevated levels of 
tPA in CSF (Akenami et al., 
1996)
All of the RNA-intact samples, 
shown by in situ hybridization 
using glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) 
probe (positive control probe, 
DAKO), were negative for 
EBER RNA. From five samples 
from patients with MS and 
from three samples from con-
trol patients RNA appeared to 
be degraded. 
HHV-6 antibodies and 
DNA in serum and CSF of 
patients with MS (II)
Eighteen of 26 (69.2%) serum 
samples from patients with 
OND contained HHV-6A anti-
bodies. All 27 patients with 
CDMS (p=0.001) and all 19 
patients with CPMS (p=0.007) 
had HHV-6A antibodies in se-
rum. No significant differences 
in HHV-6B prevalences in dif-
ferent patient groups were 
found; ten out of 27 (37.0%) 
patients with CDMS, four out 
of 19 (21.1%) patients with 
CPMS and ten out of 26 
(38.5%) patients with OND 
had HHV-6B antibodies. Multi-
plex-PCR and oligonucleotide 
arrays were utilized for the 
study of herpesviral DNA. All 
of the samples, except one 
OND CSF sample that con-
tained HSV-1 DNA, were nega-
tive for herpesviral DNA. 
HHV-6A antibody titers were 
significantly higher in patients 
with MS. The mean titer of 
HHV-6A in patients with OND 
was 27 with a standard devia-
tion (SD) of 31. In comparison, 
patients with CDMS had a mean 
titer of 87 with a SD of 101 
(p=0.005) and patients with 
CPMS had a mean titer of 118 
with a SD of 92 (p=0.00002). 
Initial HHV-6A studies in regard 
of prevalence and mean titers 
suggested an association be-
tween HHV-6A and multiple 
sclerosis, although HHV-6 anti-
body formation might be an 
epiphenomenon associated with 
autoimmune mechanisms and 
polyclonal B-cell activation. In-
deed, elevated antibody titers to 
a number of infectious agents 
have been reported. Still, one of 
the strongest links between EBV 
and MS is an altered immune 
response to EBV in MS (Sund-
ström et al., 2004).
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Avidity of HHV-6A and HHV-
6B was investigated by elution 
of low-avidity IgG antibodies 
with urea. One of the patients 
with OND had low-avidity an-
tibodies to HHV-6B in serum 
suggesting recent primary in-
fection with HHV-6B. None of 
the patients with either CDMS 
or CPMS had low-avidity anti-
bodies to HHV-6B. Two pa-
tients with CDMS and three 
patients with CPMS in com-
parison to one patient with 
OND had low-avidity antibod-
ies to HHV-6A suggesting re-
cent primary infection with 
HHV-6A. Although not a statis-
tically significant finding, it 
seems that HHV-6A primary 
infection in patients with MS 
might be more common than 
in patients with other neuro-
logical diseases. Low-avidity 
antibodies are present in se-
rum two to three months after 
primary infection, and after 
that B-cells have matured and 
high-avidity antibodies are 
produced. The time frame is 
quite narrow if related to the 
relatively slow progression and 
development of the chronic 
disease, like multiple sclerosis, 
and therefore it is possible that 
the number of primary HHV-
6A infections among the pa-
tients with MS could be even 
higher, if looked at the right 
time. An interesting observa-
tion was that the largest pro-
portion of subjects that had 
low-avidity antibodies were 
patients with possible MS. 
These patients possibly have 
MS, although it is not definite-
ly diagnosed. Typical to these 
patients is that they are in the 
early phase of the disease, and 
therefore, presence of low-
avidity antibodies might sug-
gest a temporal association be-
tween the onset of the disease 
and HHV-6 infection.
To get further information on 
the role of HHV-6 in MS, cor-
responding CSF samples from 
the same patients were studied 
for HHV-6 IgG antibodies. All 
of the CSF samples, including 
patients with MS and OND, 
were negative for HHV-6B IgG. 
All of the patients with OND 
were also negative for HHV-6A 
IgG, but three patients with 
CDMS (11.1%, p=0.06) and 
four patients with CPMS 
(21.1%, p=0.01) had HHV-6A 
IgG in CSF. Either the antibod-
ies are infiltrated from serum 
to CSF through broken blood 
brain barrier (BBB) or antibod-
ies are produced within CNS 
as a result of viral CNS infec-
tion.
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Intrathecal HHV-6 antibody 
production in MS (II)
Two patients with CDMS and 
three patients with CPMS had 
an abnormal AbI ratio sugges-
tive of intrathecal antibody 
production. One patient with 
positive CSF finding in each 
patient group had unremark-
able AbI probably suggesting 
infiltration of IgG from serum 
to the CSF. The breakdown of 
the BBB in MS might lead to 
increased transmission of se-
rum molecules like immuno-
globulins to the central ner-
vous system and CSF. Thus it 
is important to compare CSF 
antibody findings to the corre-
sponding serum antibodies 
and preferentially correct the 
results with total IgG content. 
Altogether two out of 27 
(7.4%) of patients with CDMS 
and three out of 19 (15.8%) of 
patients with CPMS had in-
trathecal antibody production. 
Derfuss et al. (2005) found in 
their study that 8/38 (21.1%) 
of patients with definite MS 
and 4/13 (30.8%) of patients 
with possible MS had intrathe-
cal antibodies. In their study 
the number of patients with 
intrathecal HHV-6 antibodies 
was even higher and supports 
together with our results that 
there is a subgroup of patients 
that have intrathecal immune 
response against HHV-6. Al-
though Derfuss and others 
(Derfuss et al., 2005) postulate 
in their article that their results 
excludes HHV-6 as a cause of 
MS in majority of patients 
(non-intrathecal HHV-6 anti-
bodies), it is not excluded that 
HHV-6 acts as a trigger in early 
disease by a “hit and run” 
mechanism. They also suggest 
that specific intrathecal anti-
body production is either the 
consequence of more frequent 
reactivation of the virus or it 
could be part of polyspecific 
IgG production. We suggest a 
third option in which primary 
HHV-6A infection might act as 
a trigger and in some cases the 
infection invades CNS and be-
comes chronic. This might 
partially clarify our results that 
we found low-avidity antibod-
ies more frequently from the 
patients with CPMS. It might 
be that activated B-cells pro-
ducing HHV-6 antibodies have 
not reached the CNS yet. Inter-
estingly, the two definite MS 
cases who had intrathecal an-
tibodies were both patients 
with past HHV-6 infection sug-
gesting chronic infection.
Intrathecal antibodies have 
been reported to be directed 
against other viruses and bac-
teria as well. These infectious 
agents include measles, rubel-
la, VZV and Chlamydia pneu-
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moniae (Sindic et al., 1994; 
Luxton et al., 1995; Reiber et 
al., 1998; Derfuss et al., 2001).
HHV-6 specific oligoclonal 
IgG bands in MS (III)
Nine patients with MS, four 
CDMS and five CPMS, collect-
ed from the initial patient pop-
ulation used in study II, were 
further analyzed for the pres-
ence of oligoclonal bands. The 
patients were included to the 
study using positive HHV-6 IgG 
CSF or low-avidity HHV-6 IgG 
antibodies in serum as inclu-
sion criteria. All four patients 
with definite diagnosis had 
OCBs and one out of five pa-
tients with possible diagnosis 
had OCBs. The specificity of 
the bands to HHV-6 was then 
studied. In two patients with 
definite diagnosis the bands 
reacted with HHV-6 antigens, 
both HHV-6A and HHV-6B. 
These patients both had been 
serologically determined to 
have past HHV-6 infection. In 
two OCB-positives, HHV-6-
OCB-negative, HHV-6 infection 
was serologically suggested to 
be an acute primary infection. 
Thus it might be that HHV-6 
first infects peripheral com-
partments and invades CNS 
thereafter and generates a 
chronic CNS infection, after 
which oligoclonal HHV-6-spe-
cific antibodies are produced. 
We compared CNS-specific 
banding pattern from MS pa-
tient that reacted with HHV-6 
to banding pattern seen in 
HHV-6 reactivation case. In the 
control case the banding pat-
tern was clearly different, 
strong OCBs were seen in se-
rum but only faint bands in 
CSF. This was clearly opposite 
to what we noted in MS. In 
these patients virus was clearly 
linked to the etiology of the 
disease. In addition, HHV-6-
specific OCBs did not react 
with HSV-1, although a control 
case with possible HSV en-
cephalitis reacted with HSV-1 
antigen, showing no cross-re-
action between these two vi-
ruses.
The presence of autoantibodies 
in MS is well characterized; 
however, the specificity of the 
autoantibodies is not well 
specified (Lovato et al., 2008). 
It is evident that some of the 
OCBs are directed against sel-
fantigens including myelin 
components. Besides selfanti-
gens, some infectious antigens 
including two EBV proteins 
(Cepok et al., 2005) and mea-
sles antigen (Vandvik et al., 
1976) have been reported to 
react with OCBs.
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Table 5. HHV-6 antibody findings in nine selected patients with MS
No Diagnose HHV-6 status HHV-6 IgG CSF/ITAP OCB/HHV-6 OCB
1. CDMS Past +++/+ +/+
2. CDMS Primary -/- +/-
3. CDMS Past ++/+ +/+
4. CDMS Primary ++/- +/-
5. CPMS Primary +/+ -/-
6. CPMS Primary +/+ -/-
7. CPMS Past +/+ -/-
8. CPMS Primary -/- -/-
9. CPMS Past +/- +/-
HHV-6A primary infection in children with 
neurological symptoms (IV)
Forty-one children of 53 (77%) with suspected encephalitis had 
HHV-6A antibodies. Six of them (Table 5) had low-avidity anti-
bodies in their serum suggesting temporal relation with primary 
HHV-6 infection and neurological symptoms. The mean age of 
children with primary infection was significantly lower than that 
of others (2.3 vs. 6.9 yrs). Three children (Nos 1, 2, 3) had no 
other virological findings in extensive studies. Two of them (1, 2) 
also had evidence of HHV-6 DNA, one in serum and one in CSF; 
anyhow we were not able to identify the variant by PCR. The 
third child was negative for HHV-6 DNA in serum, and CSF sam-
ple was not available. One child (No 6) with low-avidity antibod-
ies to both HHV-6A and HHV-6B had also HHV-6 DNA in CSF, 
but had also Coxsackie B5 in stool and antibodies to both adeno-
virus and Coxsackie B5 in CSF. 
Table 6. HHV-6 DNA findings in children with low-avidity antibodies.
No Low-avidity antibodies Serum DNA CSF DNA
1. HHV-6A - (+)*, -
2. HHV-6A + -
3. HHV-6A - NA
4. HHV-6A - NA
5. HHV-6B - -
6. HHV-6A&B - +
*positive on day 1, negative on day 15; NA, not available
Altogether 6/53 (11.3%) children with neurological symptoms 
had low-avidity antibodies in their serum. In three cases the pres-
ence of virus was confirmed by PCR, only one in serum. This is 
however, to be expected since DNA appears transiently in serum, 
usually before the appearance of antibodies. Unfortunately, CSF 
samples were not available from all of the patients. 
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Concluding remarks  
 and perspectives
Human herpesvirus 6 (HHV-6) 
is a very neurotropic virus. It 
has been shown to be one of 
the most prominent infectious 
candidates to play a role in the 
pathogenesis of MS. However, 
the nature of the virus, its 
ubiquity, latency, viral DNA 
integration into host genome, 
as well as methodological dif-
ferences have resulted in con-
troversial reports on the asso-
ciation of HHV-6 and MS. 
Since it is obvious that con-
ventional Koch’s postulates, 
e.g. infectious agent must be 
found in every case and not 
present in any control case, do 
not apply in this situation, we 
need to devise new approaches 
to clarify the role of such infec-
tious agents that do not cause 
disease in everyone. Koch’s 
postulates are more applicable 
for bacteria than viruses. At-
tempts to create more applica-
ble criteria for the disease cau-
sation have been developed for 
commensal viruses (for review 
see, Fredricks and Relman, 
1996). 
In our stud-
ies we were 
able to 
show an 
expression 
of HHV-6 
antigen in MS brain autopsy 
samples. The expression of 
HHV-6 antigen was more fre-
quent in MS cases than in con-
trols. We also showed in-
creased prevalence of HHV-6 
antibodies both in serum as 
well as in CSF. The presence of 
IgG low-avidity antibodies to 
HHV-6 in serum suggested 
more recent acquisition of the 
virus. Interestingly, most cases 
with recent exposure to HHV-6 
were possible MS cases. This 
might suggest that HHV-6 have 
a role at the early disease. Oth-
ers have also reported that 
HHV-6 infection might be more 
common in early disease, by 
detection of HHV-6 DNA by 
PCR (Rotola et al., 2004) or by 
detection of HHV-6 IgM (Villo-
slada et al., 2003). In some MS 
cases antibodies were found in 
the CSF, no HHV-6 antibodies 
were found in CSF of patients 
with OND. Antibodies were 
shown to represent antibodies 
that are synthesized locally 
within the central nervous sys-
tem suggesting a CNS infec-
tion. 
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We were able to identify OCBs 
in the CSF of two patients with 
MS that reacted with HHV-6 
antigen. This suggests direct 
involvement of HHV-6 in the 
formation of OCBs, which are 
one of the hallmarks of MS 
and therefore suggests HHV-6 
as a causal agent in these pa-
tients. This is a first time that 
specificity of HHV-6 to OCBs 
has been shown. Some EBV 
proteins, as well, have been 
shown to react with OCBs; 
however, we showed that 
HHV-6 viral antigen reacted 
with most if not all of the 
OCBs present in CSF. This im-
plies that HHV-6 is a major an-
tigenic force driving the immu-
nological response and 
formation of OCBs in these pa-
tients. The EBV proteins that 
have been shown to react with 
OCBs are EBNA-1 and BRRF2 
(Cepok et al., 2005). BRRF2 is 
an uncharacterized protein and 
EBNA-1 is a latent protein. 
However, most of the studies, 
including ours (I), have been 
unable to show EBV within 
CNS.
Studies comprising this thesis 
supported the association of 
HHV-6 and MS in some cases. 
However, it seems probable 
that there is no single infec-
tious cause for MS; instead 
many different pathogens 
might act as triggers in the de-
velopment of the disease. The 
strongest candidates thus far 
are HHV-6 and EBV.
HHV-6 is predominantly re-
garded as a childhood virus 
that causes ES. Besides ES, 
primary infection may cause 
febrile seizures and infections 
of the CNS. We studied the 
presence of low-avidity IgG 
antibodies in children with 
suspected encephalitis. We 
found a remarkable number of 
children who had low-avidity 
IgG antibodies to HHV-6 con-
comitantly with the signs or 
symptoms of encephalitis sug-
gesting a significant involve-
ment of HHV-6 as a causal 
agent of encephalitis at young 
ages. HHV-6 might be a under-
appreciated cause of encepha-
litis both in immunocompro-
mised as well as in 
immunocompetent individuals. 
It is important to test for 
HHV-6 in patients with en-
cephalitis of unknown etiolo-
gy.
Carefully designed clinical tri-
als using efficient antiviral 
drugs to HHV-6 in selected 
cases of MS, as well as with 
encephalitis, are urgently 
needed for the clarification of 
the role of HHV-6 in MS and 
encephalitis. In case studies, 
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antiviral drugs like ganciclovir, 
have been successfully used 
for the treatment of HHV-6 en-
cephalitis. Unfortunately, there 
have been no well-defined 
clinical trials for efficacy of an-
tiviral drugs in the treatment 
of HHV-6 infection. The drugs 
used currently for the treat-
ment are drugs that are used 
for the treatment of CMV. Both 
in vitro experiments to seek for 
new antiviral compounds and 
carefully designed clinical tri-
als are needed to establish ef-
fective treatments for HHV-6 
infection. Furthermore, special 
attention should be given to 
the development of suitable 
animal models for the study of 
HHV-6 pathogenesis. The find-
ing of HHV-6 specific OCBs in 
MS is of special interest and 
needs to be further confirmed 
and evaluated in larger patient 
populations. 
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